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Introduction 
Chapter J 
1.1 Iron metabolism 
"The versatility of uses Nature has found for iron originates in the simple aqueous 
chemistIy of this essential transition metal. Of the diverse chemical reactions of iron in 
solution the most important is the facile and reversible one-electron 
oxidation-reduction reaction that takes iron between its two common oxidation states, 
the fenous and the ferrief( (1). It is for this reason that iron is a key element in many 
biochemical processes and shortage of iron causes damage to cells and organs. On the 
othcr hand it is also this feature which makes iron one of the most harmful clements, 
because it is able to catalyse the formation of highly reactive oxygen and hydrogen 
radicals when present in the unbound state. These radicals can cause permanent 
damage to intracellular proteins and DNA. 
Almost all organisms from micro organisms and plants up to the higher organisms like 
humans require iron, but at a neutral pH thc solubility product of iron is extremely low 
(Fe(OH), = 4xlO'''), which makes iron almost insoluble. For this reason proteins have 
developed to manage the storage and transport of iron bet\veen cells. 
1.1,1 Iron uptake 
The body's iron status is almost completely dependent on the dietary intake. The 
gastrointestinal tract plays a major role in maintaining iron balance, especially the 
mucosa cells of the uppcr intestine (2). 
To study iron absorption a distinction has to be made between the absorption of haem 
iron and non-haem iron. The major source of haem iron is food derived from animal 
tissues with haemoglobin and myoglobin being the main precursors. Non-haem iron is 
mainly derived from foods of both plant and animal origin. Thc bioavailibility of iron 
from haem components is much higher than that obtained from non-haem 
components. 
Absorption of iron from both haem and non-haem components is greatly influenced by 
the body iron stores and is increased in the case of iron deficiency. This relationship, 
however, is less pronounced for haem iron (2). 
Haemoglobin is converted to haem in the digestive tract. The haem molecule is taken 
up by the mucosa cell by a spccific receptor and after cleavage from the haem 
molecule iron enters the intracellular pool of iron. The absorption of non-haem iron is 
more complicated and depends on more factors. In the first place bioavailability is 
different in different foods. Secondly a low pH of the gasttic juice is required to 
solubilise iron and probably mucosa factors are important. Apart from that, enhancers 
of iron uptake can influence the bioavailability. An example of such an enhancer is 
ascorbic acid which enhances the uptake by reducing the ferric to the ferrous state and 
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by its action as a chelator in the stomach and small bowel to keep iron in solution. In 
some foods inhibitors of iron uptake may interfere with the absorption process. These 
can be found in cereals and some vegetables so contributing to the development of 
iron deficiency in vegetarian diets. 
The precise mechanism of iron uptake has not yet fully been understood but it is 
supposed to be a combination of non-specific binding and specific uptake by a 
receptor or proteins which act as a shuttle (2). The regulation of iron uptake by the 
mucosa cell is dependent on the iron status and on the rate of erythropoiesis. 
After uptake by the mucosa cell iron will either be stored in the mucosa cell or 
transported to the basoIateral site of the cell where iron enters the blood. The precise 
mechanisms have not yet been clarified (2). In the scmm iron binds to transfcnin, an 
80 kDa glycoprotein which has as main function the transfer of iron between sites of 
absorption, utilisation and storage (3,4). 
1.1.2 Iron distribution 
As has been stated before, the iron status is regulated at the level of iron uptake instead 
of at the Icvel of iron excretion. The average iron secrction and uptake is 1 mg per day. 
The body of an adult male contains about 4 grams of iron (table I. I). Almost two 
thirds of the total amount of body iron is incorporated in haemoglobin and myoglobin 
(5,6,7). In females the need for iron is increased in the fertile period of life due to 
increased loss as a result of menstruation and pregnancy. 
Table 1.1 - Aperage overall distribution a/iron ill the humall body, male 75 kg 
(adaptedfmlll 7). 
mg iron175 mg iron/kg 
kg 
functional haemoglobin 2,300 31 
iron 
myoglobin 320 4 
haem enzymes 80 1 
non-haem enzymes 100 1 
transferrin 4 0.05 
storage iron ferritin 700 9 
haemosiderin 300 4 
total 3,800 50 
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Another group of patients at risk for developing iron deficiency is the child. Especially 
in age groups where rapid growth and development are combined with a high 
susceptibility to infections iron present in the food often does not match the 
requirements. This effect is even more important when the intake of food is 
insufficient (8,9). Many children develop iron deficiency anaemia which can, in 
advanced cases lead to impaired growth and central nervous system dysfunction. 
Studies in school children reveal that iron deficiency anaemia is accompanied by poor 
IQ test score. Some studies indicate that in this age group correction of the iron 
deficiency anaemia is not accompanied by improved IQ performance (8, 10, 11,12). 
However, a recent study has found the opposite (13). More research is required but 
attention has to be paid to the study design and the analytical methods used (14). 
1.1.3 Iron storage 
The storage protein for iron is ferritin. Ferritin consists of an apoprotein shell, Mw 480 
kDa, surrounding a core which can contain up to 4,500 iron atoms in the form of the 
mineral ferrichydrite. The apoprotein is built up of 24 subunits. Two structurally 
distinct subunits can be found: the H and the L subunit. Differcnt isoferritins can be 
found built up of different proportions of the two subunits. Different isoferritins can 
be found in different tissues. Isoferritins with an increased percentage of H-subunits 
are mainly found in organs like the heart and red blood cells, which are not primarily 
concerned in iron storage. On the contrary, isoferritins with increased percentages of 
L-subunits are predominantly found in tissues involved in iron storage such as the 
liver and the spleen (15). 
The process of iron uptake into the ferritin shell has not been clarificd yct. The hollow 
shell displays 14 channels through which iron can enter the core (7,16,17). Iron is 
generally taken up in its ferrous fonn, which is oxidised to the fcrric form at the outer 
slllface by a ferroxidase centre located on the ferritin H-chains (7,15,18,19). Ferric 
iron is stored in the core of the apoferritin in complex with oxygen and phosphorous. 
Iron release in vivo is thought to occur in lysosomes or endosomes with an acid pH 
(15). The precise mechanism, however, is still unknown. 
It has been postulated that a difference in subunit composition could lead to a 
difference in function between the isoforms of ferritin (7,16,17,20,21). This would be 
caused by the location of fen'oxidase, which is exclusively located on the H-chain. As 
a result of this, isoferritins which are rich in H-subunits can take up "free" iron more 
rapidly. In the acute phase response the production of H-rich ferritin is stimulated. 
The serum concentration of ferritin is used as a diagnostic tool in the assessment of 
iron status (22). In iron deficiency the serum ferritin concentration has been shown to 
correlate very well with iron stores. However, in those cases in which iron deficiency 
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is complicated by an acutc phase reaction, the ferritin concentration can be elevated as 
a result of this despite the prcsence of depleted iron stores (22,23,24). Additionally, 
the serum ferritin concentration is a good indicator of iron stores but gives little 
information as to the severity of iron deficiency (22). 
Recently, a method has been described to determine the iron concentration of felTitin. 
It has been postulated that this parameter should be a better indicator of iron stores 
than the serum ferritin concentration (25). 
1.1.4 Iron transport 
Iron is transported from sites of absorption to sites of utilisation or storage complcxed 
to transferrin. Transferrin is a glycoprotein (Mw 80 kDa). It consists of a single 
polypeptide chain of 679 amino acid residues. The transferrin molecule can be divided 
in two homologous domains, an N-tcnninal domain and the C-tenninal domain. Each 
domain contains an iron binding site which makes the transferrin molecule capable of 
binding two iron (FeIII) ions. Thc two iron binding sites act indcpendently of each 
other (3,7,26). To bind iron to one of the binding sites, a synergistic anion is required 
to stabilise the complex. 
At the C-tenninal domain two N-linked glycan chains arc attached. These glycan 
chains may vary in carbohydrate content and in degree of branching, sialylation and 
galactosylation (3,26). This variation is called the microhcterogeneity of transferrin. In 
different body tluids different nllcroheterogeneity patterns have been described (27). 
For example in cerebrospinal t1uid a raised percentage of asialotransferrin can be seen. 
This has been used as a diagnostic tool in the diagnosis of cerebrospinal tluid leakage 
in case of rhinorrhea or otorrhea. Also in certain clinical conditions different 
microheterogeneity patterns have been observed (28). One example is the appearance 
of an increased fraction of carbohydrate deficient transferrin (CDT) in case of high 
alcohol intake (29,30,31). A diagnostic test based on this principle has been developed 
(32). 
Synthesis of transferrin mainly occurs in the hepatocyte in the liver. Transferrin 
synthesis starts with the association of rnRNA and ribosomes in the cytoplasm. 
Initially a polypeptide chain is formed which is 19 amino acids longer than the final 
moleculc. After translocation to the rough endoplasmic reticulum, the N-glycosylation 
of the protcin takes place at the two possible glycosylation sites (26). At first a 
uniform glycan is positioned at the specific sites. The processing and subsequent 
elongation of the oligosaccharide chains occurs when the protein passes through the 
different compartments of the Golgi system (26). 
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1.1.5 Transferrin microheterogencity 
As has been described before, two branched glycans arc attached to asparagine 
residues in the C-terminal domain of transfenin (figurel.I). These oligosaccharide 
chains vary in the degree of branching and sialylation. In normal semm bi-, tri- tetra-
and even penta antennary chains have been identified. Usually a sialic acid residue is 
attached to the terminal sugar of the different branches. 
Figure 1.1 - Schematic representatioll of the humall Tf molecule. 
Fe 
~ 
N c 
The glycans of transferrin are stmcturally variable. They can differ in the degree of 
branching or the terminal sialic acid molecule can be lacking. Apart from this they can 
differ in the terminal sugar residue. 
1.1.6 The transferrin rcceptor 
In 1963 the concept that cellular iron uptake was mediated by the transfenin receptor 
was proposed by Jandl and Katz (34,35). Since then much research has been done on 
cellular iron uptake and in the last decade many articles have been written on the 
stmcture and the function of the transferrin receptor. 
The transferrin receptor was found to be a dimeric structure, composed of two 
subunits linked by two disulphide bridges (figure 1.2). This transmembrane protein has 
a molecular weight of approximately180 kDa. Each monorner can be divided in an 
extracellular region, an intermediate trans-membrane region and an intracellular part. 
The intracellular part is necessary for normal endocytosis of the receptor (37,38). The 
transmembrane part functions mainly as an anchor for the protein and as a signal 
peptide for translocation across the rough endoplasmic reticulum during biosynthesis 
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(35,39,40). The extracellular part of the transferrin rcceptor is a large protein which 
contains three N-linked glycosylation sites. Oligosaccharide chains are attached to 
these sites (41,42). In addition, in some cell types O-linked glycans have been 
identified as well (43). The function of the glycan hasn't been identified yet but they 
obviously play a role in the binding of transferrin to the receptor (35,44). The affinity 
of the transferrin receptor for transferrin depends on two parameters: pH and 
transferrin iron saturation (7). At pH 7.4, the pH of the extracellular space, the affinity 
is highest for fully saturated transferrin, i.e. diferrie transferrin. However when the pH 
decreases to the pH of the endosomes, pH 5.5, the transferrin receptor affinity for apo 
transferrin increases, whereas the affinity for diferric transferrin decreases (45-48). 
Figure 1.2 - The trall.~ferrill receptor is a dimel' cOllsisting of two identical 95 kDa 
polypeptide structures. Each mOl1011ler call be divided ill (i) {( large extracellular 
regioll (empty box) with a Humber o/slIgar residues (1) attached 10 the C-Iermillal 
elld, (ii) a slIIal/ alld hydrophobic illterlllediate seglllellt (black box) that 'pallS the 
plasma membrane and (iii) a short Cytoplasmatic "tail" harbouring a pllOsphOlylatiol1 
site (P) (7). 
CO OH COOH 
- - 1 
- -
- -
Extracellular compartment 
SoS 
~~~ S- ~~~~~~~ 
VVV VVVVVVV 
Plasma membrane 
Intracellular compartment 
The transferrin receptor is present on most cells but since erythroid cells have a special 
requirement for iron due to the synthesis of haemoglobin most receptors can be found 
on erythroid tissue. In vitro studies have shown that in cell culture soluble transferrin 
receptors are released from erythroid cells mainly to the semm at the middle to late 
phases of maturation, mostly from polycln'omatic erythroblasts (49). In serum soluble 
transfelTin receptors can be found as truncated fragments of the intact cellular 
7 
Chapter I 
receptors. These li'agments appear in serum due to shedding or clcavage (50-52). The 
level of soluble transferrin receptors has been found to be directly proportional to the 
total amount of tissue rcceptors (50). Since the majority of tissuc transferrin receptors 
can bc found on erythroid cells, this is directly proportional to the erythroid mass. The 
concentration of soluble transferrin receptors in serum shows an individual variation 
around its homeostatic set point. This annual rhythm appeared to be synchronised with 
those in transferrin concentration and number of erythrocytes, while it was negatively 
related to the annual rhythms in serum iron, MCV and MCH. The intra-individual 
variation has been suggested to retlect changes in nutritional and immune status (53). 
Recently, many clinical studies have been performed regarding the concentration of 
soluble transferrin receptors in different conditions (52-62). According to some 
authors the increased concentration of soluble transferrin receptors in iron deficiency 
is a useful parameter to differentiate it from anaemia of chronic disease (24). 
Recently commercial Elisa tests have been introduced to the market for the detection 
of soluble transfcrrin receptors in serum using specific monoclonal antibodies (63,64). 
This test is expected to serve as a diagnostic tool in the clinical diagnosis of different 
types of anaemia. 
1.1.7 The cellular uptake of iron 
Most iron is taken up by the cell by means of a process called "receptor mediated 
endocytosis". After the transferrin iron complex has bound to the transferrin receptor, 
the transferrin-iron-receptor complex is internalised into the cell. All cells which have 
transferrin receptors on the cell membrane are capable of endocytosing transferrin 
(35). Several stcps in this process can be identified. Firstly, the receptors on the ccll 
surface bind transferrin and cluster into coated pits. This is followed by endocytosis, 
un coating of thc vesicles and acidification of their contents (35,26). The acidification 
of the endosome results in the release of iron from transferrin. The iron is 
subsequently released into the cytosol and apotransferrin as well as the receptor are 
recycled. Apotransferrin, which has a low affinity for the receptor at pH 7.4, is 
released into the circulation whereas the receptor is recycled on the cell membrane 
ready to bind iron-transferrin again (35,26). 
1.1.8 Intracellular iron homeostasis 
The expression of transferrin receptors on the cell membrane and the production of 
intracellular ferritin have been shown to be linked and both depend on the intracellular 
iron content (figurel.3). An interesting fine tt1ning system has been described which 
regulates the iron uptake at the molecular level, the "iron responsive clement" 
(65,66,67). The iron responsive elements (IRE's) arc short sequences in the mRNA of 
ferritin and erythroid 5-aminolevulinate synthase as well as in the mRNA of the 
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transferrin receptor. These hairpin shaped structures are located either at the 5' 
untranslated region of ferritin mRNA or at the 3' untranslated region of transferrin 
receptor mRNA. Although an RNA secondary structure within the 5' untranslated 
region of an mRNA can directly innuence translation, the prcdicted stability of the 
ferritin IRE stem loop is insufficient to be likely to impede translation on its own 
(67,68,69). In fact, evidence has been gained which suggests that the IRE alone is a 
positive effector of ferritin translation (66,70). In human celllysates a cellular factor 
was identified which was capable of interacting specifically with an RNA transcript 
containing an IRE (71). This factor was identified as the IRE-binding proteins 
(IRE-BP's). The IRE's are the target structures of the IRE-BP's. The IRE-BP has a 
structure similar to aconitase, an enzyme in the citric acid cycle (72,73). 
Figure 1.3 - Schematic presentation of the interaction between the iroll responsive 
eiemellt (IRE) alld the iroll billdillg proteill (IRE-BP) alld the ~[fects of this illteractioll. 
Depending 011 the intracellular iroll cOllcentratioll eitherferritill or the transferrin 
I'eceptol' is produced (7). 
Intracellular iron concentration low 
• Iron Responsive Element - Binding Protein activity high 
Ferritin 
~ Y Ferritin mRNA t--
TranSfe~ecePtor 
----iTransferrin receptor mRNAI~ 
Intracellular iron concentration high 
• Iron Responsive Element - Binding Protein activity low 
Ferritin 
~ Y Ferritin mRNA t--
TranSfeieceptor 
----j T "nsferrin receptor mRNA IITITITITIl 
~ Iron responsive element 
n Iron responsive element - Binding protein 
The IREIlRE-BP system functions as a fine tuning system regulating the production of 
both ferritin and the transferrin receptor depending on the intracellular iron 
concentration. In case of a high intracellular iron concentration, the IRE-BP will 
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contain several molecules of iron. This makes the enzyme unable to bind to an IRE) so 
enhancing the synthesis of ferritin. In the case of a reduced intracellular iron 
concentration, the IRE-BP is activated and will bind to the IRE's. Thc binding of the 
IRE-BP to the IRE on the 5' un translated region on the ferritin mRNA inhibits the 
production of ferritin. At the same time the IRE-BP will bind to thc 3' untranslated 
region of the transferrin receptor, so stimulating the production of thc transferrin 
receptor by blocking rapid degeneration of this transferrin receptor mRNA (7,66,74). 
1.1.9 Iron metabolism in pregnancy 
In pregnancy many physiological changes occur, as a result of the great demands of 
the foetus on the maternal metabolism. Despite the amenorrhea) pregnancy places a 
significant demand on iron homeostasis (75). 
The foetus requires large amounts of iron) having the maternal iron stores as the only 
donor. In humans 23% of the maternal iron stores is transported to thc foetus, mainly 
in the third trimester (76,77,78). 
Much research has been done on transplacental iron transport. The placenta has been 
shown to be autonomous in iron uptake, with iron transport acting as a one way 
process towards the foetus (78,79,80). This process is active, operating against a 
concentration gradient. The amount of iron transported to the foetus increases towards 
the end of pregnancy. In the second trimester approximately 0.4 mg iron per day is 
transported across the placenta rising to 5 mg iron per day at term (76,78,80). 
The human placenta is composed of a cellular trophoblast layer consisting of an inner 
layer of cytotrophoblast cells and an outer laycr of multinucleated syncytiotrophoblast. 
The syncytiotrophoblast layer develops by fusion of numerous cells resulting in a 
multinucleated layer without cellular membrane. The syncytiotrophoblast layer has an 
apical side facing the maternal blood and a basal side resting on the cytotrophoblast 
cells and a basement membrane. As pregnancy progresses, the number of 
cytotrophoblast cells decrcascs. At term only 20% of these cells are still present. The 
human placenta has a villous structure. The foetal trophoblast villi project into lacunas 
filled with maternal blood. The distance between the maternal and the foetal 
circulation decreases as pregnancy progresses by fusion of the cytotrophoblast and the 
syncytiotrophoblast cells. This facilitates diffusion (77 ,81-84). 
Transferrin receptors are present abundantly on both the apical and the basal cell 
membrane of the syncytiotrophoblast cells (77,86-92) and in very low concentrations 
on freshly isolated cytotrophoblasts (77). It has been shown that the expression of 
transferrin receptors on cytotrophoblast cells is part of the biochemical differentiation 
towards the syncytiotrophoblast (93,94). In culture the number of transferrin receptors 
depends on the iron concentration in the culture medium (95-97). In vivo the 
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expression of transferrin receptors on the syncytiotrophoblast layer depends on the 
foetal need for iron. Maternal transferrin can bind to the placental transferrin receptor 
and iron uptake can occur by receptor mediated endocytosis as has been described for 
other cell types. 
As has been described by Dc Jong (26) the microheterogeneity pattern of transferrin is 
redirected towards the synthesis of highly sialylated transferrins as pregnancy 
progresses. The effect becomes statistically significant in the sccond trimester and this 
trend appeared to be continued up to the last week of pregnancy. After delivery the 
pattern rapidly changes to normal again within a period of 5 weeks (26). The 
physiological signiticance has not been identified yet, but an increased mobilisation of 
iron from the liver due to an increased concentration of the highly sialylated fractions 
has been proposed (26). 
1.1.10 Foetal development of erythropoiesis and iron metabolism 
During foetal development the first sign of haematopoiesis is the appearance of "blood 
islands" in the mesenchyma, lateral to the primitive streak at 2 to 3 weeks after 
fertilisation. At 16 days of gestation pluripotent stem cells arise in the yolk sac. These 
cells give rise to different cell lines and erythroid cells. Primitive forms of 
haemoglobin can be detected early after gestation. As pregnancy progresses the 
erythropoiesis moves from the yolk sac and intravascular erythropoiesis to the liver 
and the bone marrow. The liver becomes the main place of erythropoiesis by 
approximately 8 weeks of gestational life, whereas the bone marrow acquires this 
function at about 28 weeks of gestational life (98,99). 
Erythropoiesis is the result of a finely tuned system of stimulators and inhibitors. The 
factors influencing erythropoiesis are diverse and act on different stages of erythroid 
development. Metcalf has proposed a model in which all haematopoietic cells are 
organised in subsequent compartments. As a certain cell develops from one 
compartment to the next it loses the ability of self replication but every subsequent 
compartment is larger and more differentiated (100,1O1). 
The pluripotent stem cells arc usually in the resting GO stage but are capable of 
differentiating into onc of the lineage specific progenitor cells (figureI.4). From the 
pluripotent stem cell the colony forming unit arises that can differentiate into 
erythroid, myeloid, monocytic and meagakaryocytic cell lines. The several cell lines 
that develop from this CFU-GEMM proliferate and differentiate into circulating blood 
cells. This process of proliferation and differentiation is influenced by several 
hormonal and micro-environmental factors (l 02, I 03). 
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Figure 1.4 - Hierarchy ofhaelllatopoiesis (104). 
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As the erythroid progenitor cell develops through erytlu'opoiesis the cell matures into 
the erythrocyte thereby developing various membrane antigens (figures 1.5 and 1.6). 
From the earliest stage the transferrin receptor can be detected on the cell membrane. 
The transferrin receptor is lost from the membrane at the stage of the reticulocyte 
(105). From the stage of the erythroblast until the erytln'ocyte glycophorin appears on 
the cell membrane. 
t2 
illtrodflctioll 
Figure 1.5 - Schematic representation of the various stages of elythroid differentiation 
(106). 
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1.1.11 Iron metabolism of infancy and childhood 
In the newborn infant polycythemia is usually found as a result of intra uterine 
hypoxia. After birth the oxygenation improves markedly leading to a depression of 
erythropoiesis. This can be shown by a cessation of erythropoietin production after the 
second day of life (107, I 08, I 09). 
The two determinants of iron status at birth are birth weight and haemoglobin mass 
(table 1.2). The body iron content of the newborn is relatively constant over a wide 
range of maternal iron reserves (110). 
Table 1.2 - Relationship a/birth weight to total body iron at birth (adapted/mm 110). 
birth weight (kg) 
l.5 
2 
2.5 
3 
3.5 
total body iron (mg) 
120 
160 
200 
240 
280 
The foetus seems to be an effective parasite for iron. Iron administered to the mother 
during pregnancy does not influence the iron status of the newborn and the 
haemoglobin concentration of blood from infants born to mothers with i.ron deficiency 
is normal (110-115). In a recent study the relation between maternal serum ferritin 
concentration and the foetal erythrocyte fen·itin content was compared for different 
groups of patients (116). This study indicates that maternal erythropoiesis and the 
foetus compete for iron in the case of shortage for iron. During the first weeks of life 
iron shifts from erythropoiesis towat'ds the storage pools as the haemoglobin 
concentration falls. As a result the infant is able to double its birth weight without 
exhausting the iron reserves. Thereafter iron absorption becomes the critical factor in 
maintaining a normal haemoglobin concentration (110,117,118). For term infants the 
iron reserve at birth is sufficient for the first 5 months of life. Preterm infants, 
however, only can)' enough iron for up to the first two months. These changes are also 
reflected in the ferritin concentration. At birth the ferritin concentration is high and it 
increases during the first weeks of life as iron stores expand. As erythropoiesis 
increases again the ferritin levels fall. The same pattern is seen in premature infants, 
all though the ferritin levels are lower (110,119-123). An even better indication of the 
foetal iron stores could be gained from the foetal erythrocyte ferritin concentration 
(116). 
The iron status during infancy is important for the long term development in children. 
Iron stores at birth have been shown to correlate very well with iron stores at 6, 9 and 
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12 months of age (125). Both iron deficiency and iron overload have an adverse effect. 
Children who develop iron deficiency anaemia in infancy have a higher risk of 
long-lasting developmental disadvantages compared to their peers with better iron 
status (126). In contrast to adults detectable levels of non protein bound iron can be 
found in up to 25% of healthy newborns (127, 128). In a recent study the relationship 
has been studied between the severity of birth asphyxia, plasma concentration of 
non-proteinbound iron and TBARS (thiobarbituric-acid-reactive species). It was found 
that there appearcd to be an association between an elevation of the non-proteinbound 
iron concentration and an adverse outcome after severe birth asphyxia. On the other 
hand all the severely asphyxiated children with no detectable non-proteinbound iron in 
their plasma had a normal neuro developmental outcome at I year of age (129). 
1.2 MyeJodyspJastic syndromes 
The myelodysplastic syndromes consist of a heterogeneous group of primary 
haematological disorders which are usually characterised by a discrepancy between a 
cytopenia in blood and cellular or hypercellular bone marrow aspirations. In 1982 the 
French American British (FAB) Co-operative Study group tried to classify these 
disorders which were earlier referred as preleukemia. smouldering leukaemia's or 
refractory anaemia (130,131). A new classification system was made and these bone 
marrow disorders were termed myelodysplastic syndromes (MDS). 
1.2.1 Classification and morphological characteristics 
In the group of MDS five subtypes can be found: Refractory Anaemia (RA), 
Refractory Anaemia with excess blasts (RAEB), Refractory Anaemia with excess 
blasts in transformation (RAEBt), Refractory Anaemia with ring sideroblasts (RARS) 
and Chronic Myelo Monocytic Leukaemia (CMML). These different forms can be 
distinguished on both morphological and numerical findings in blood and bone 
matTOW (table 1.3). In all subtypes abnormalities can be found in the erythroid, 
myeloid and megakat-yoeytic lineages. MDS may either be apparently primary or may 
evolve in the course of other bone marrow diseases or be secondary to previous 
exposure to cytotoxic chemotherapy, irradiation or environmental toxins. 
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Table 1.3 - The FAR-classificatioll of the myelodysplastic sYlldrames (adapted/ram 
134). 
category blood bone marrow 
refractory anaemia (RA) anaemia blasts < 5% 
blasts 1 % ring sideroblasts 15% of ANC 
refractory anaemia with anaemia blasts < 5% 
ring sideroblasts (RARS) blasts 1 % ring sideroblasts > 15% of ANC 
refractory anaemia with anaemia blasts 5 . 20% 
excess of blasts (RAEB) blasts 5% 
refractory anaemia with blasts> 5Jt blasts 20 . 30%, or the 
excess of blasts in ± Auer ro s presence of Auer rods 
transformation (RAEB·t) 
chronic myelomonocytic 
leukaemia (CMML) 
blasts < 5% 
monocytes > Ix 
109/1 
blasts up to 20 % 
promonocytes often increased 
The myelodysplastic syndromes have been found to be clonal in origin arising from 
the multipotent stem cell (131,132). Usually at least two maturation lineages are 
involved but the defect may be principally manifest in onc lineage (133,134) (figures 
1.7 and 1.8):-
(a) cl)lthropoiesis: Dyserythropoiesis often leads to anaemia which can be 
normocytic, microcytic or macrocytic. In the blood film many abnormalities 
can be found like anisocytosis and poikilocytosis, circulating nucleated cells 
which may show dyselythropoietic or megaloblastic features or basophilic 
stippling. Erythropoiesis is often increased in usually hypercellular bone 
marrow aspirations showing megaloblastic erythropoiesis with dysplastic 
features like multinuclcairity, nuclear lobulation and fragmentation, 
Howell-Jolly bodies, inter-nuclear bridges, increascd pyknosis and gigantism. 
In some cases ring sideroblasts can be seen; 
(b) granUlopoiesis: In blood neutropenia is most frequently seen, although 
neutrophilia does not exclude the diagnosis lvIDS. Abnormalities in the 
nucleus or cytoplasm which could be indicative for the diagnosis are: acquired 
Pelger-Huet anomaly, bizarre shaped nuclei, increased chromatin clumping, 
hypersegmented nuclei, hypo- or agranular cytoplasm, cytoplasmic basophilia 
in mature cells and Dohle bodies. Apart from dysgranulopoictic features 
numerical and maturation defects are found in some sub types: monocytosis, 
promonocytes and blast cells (sometimes with Auer rods). In bone marrow 
smears granulopoiesis can be eithcr increased or diminished with 
hypogranular or hypergranulm' promyelocytes and hypogranular myelocytes. 
A maturation an'est can be seen as a Jack of mature neutrophils. 
Granulopoiesis is usually morphologically abnormal showing the same 
characteristic as seen in blood. The number of blasts can be increased; 
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(c) thrombopoiesis: Apart from reduction or increase in thc number of 
megakaryocytes different morphological abnormalities can be found including 
micro megakaryocytcs, large mononuclear megakmyocytes or large 
hypersegmented forms with multiple small nuclei. In blood the presence of 
giant platelets or bizarre shaped platelets suggests a diagnosis of MDS. 
Figure 1.7 - Bone marrow aspiratioll ola patient with MDS showing gigantislJl and 
l1uclear/ragmentatioll. 
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Figure 1.8 - Ring sideroblasts ill a bone marrow aspiration of a patient with RARS. 
1.2.2 Clinical picture 
In most patients a persisting anaemia is often the first sign of disease. In many cases 
therapy with iron has been given for some time without affecting the haemoglobin 
concentration and eventually many patients become transfusion dependent. Most 
patients present at middle or older age but the diagnosis has to be considered in 
younger age groups as well. Even a childhood syndrome has been described, 
associated with monosomy 7 (136). 
The long term prognosis is influenced by several factors such as patient characteristics 
and FAB classification. Patients with MDS may die as a result of bone marrow failure 
due to MDS or the MDS may transform to leukaemia (134). In some individuals 
evolution to another category of MDS happens, usually to a category with a worse 
prognosis. Also other factors may int1uence the prognosis of MDS (table lA). Several 
scoring systems have been developed to use estimate the prognosis in individual 
patients (134,137-143). 
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Table lA - Factors which have been reported to be o/prognostic significance ill ,l1DS 
(adaptedfmm 134). 
factors indicating a good factors indicating a poor 
prognosis prognosis 
clinical features younger age older age 
female male 
de novo MDS secondary MDS 
splenomegaly (CMML) 
FAB-category RA or RARS RAEB or RAEB·t 
blood features anaemia, neutropenia, 
thrombocytopenia, presence 
of blasts, neutrocytosis, 
monocytosis (CMML) 
bone marrow increased number of blasts, 
aspirate dysgranulopoiesis, 
dys m egaka ryopoies is, 
reduced megakaryocytes 
bone marrow biopsy abnormal localisation of 
immature precursors (ALlP) 
ferroki netics near normal iron low iron utilisation at 14 
utilisation at 14 days days, increased ineffective 
erythropoiesis 
karyotype normal, both normal and abnormalities of 
abnormal metaphases, chromosome 7 or both 5 
5q-, +8 or 20q· as a sole and 7; all metaphases 
abnormality abnormal; complex 
karyotype 
bone marrow culture normal numbers of reduced CFU-GM colonies or 
CFU·GM colonies and increased clusters 
clusters 
cell kinetics low labeling index 
biochemistry elevated LDH 
In the majority of cases non random cytogenetic abnormalities are commonly found 
(143). In primary MDS the most frequent abnormalities are deletions of chromosome 
5 (-515'1-), chromosome 7 (-717'1-), chromosome 20 (20'1-), or the gain of an additional 
chromosome 8. The presence of certain chromosomal abnormalities may correlate 
with survival and evolution into leukaemia (144-149), In a recent report on X 
inactivation patterns in purified sub populations of blood cells in elderly women, 
however, clonal granuloeytes and polyclonal T-cells were observed in 23 % of normal 
women and in 63 % of patients with myeloproliferative and myelodysplastic 
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syndromes (150). This suggests an age related stem cell depletion or selection. This 
also implies that clonal blood cells may probably precede rather than follow mutations 
which subsequently give rise to myelodysplastic or myeloproliferative phenotypes. 
This implies that the demonstration of clonal granulocytcs and polyclonal T-cells not a 
useful diagnostic marker in elderly women (150). 
1.3 Aim of the thesis 
The present thesis contains a study of the clinical significance of transferrin receptors 
in different clinical syndromes. In general practice many patients present with signs of 
anaemia and iron therapy is often started as a routine. This often leads to iron overload 
in patients with anaemia of chronic disease and in patients with myelodysplastic 
syndromes. In this thesis the clillical significance of the transferrin receptor as a 
predicting parameter for the efficiency of iron therapy was studied. 
Another group of patients who are often treated with iron supplements are children. In 
(premature) infants transfusions can add to a state of iron overload, which has to be 
prevented. The duality of iron, being both an essential and a noxious agent, makes iron 
metabolism in the infant a fascinating topic. In this thesis the concentration of soluble 
transfenin receptors was studied in (premature) infants in the first days of life. To 
make interpretation of the results possible the microhelerogeneity of transferrin was 
studied as well. 
The following issues were sludied:-
(a) Different commercially available tests for the evaluation of soluble transferrin 
receptors in serum were evaluated. The clinical and analytical implications 
were studied. 
(b) In patients with different types of anaemia the membrane expression of 
transferrin receptors on erythroblasts in bone marrow was studied with a 
newly developed flow cytometric method. 
(c) The relationship between the cellular expression of transferrin receptors on 
erythroblasts in the bone marrow and the concentration of soluble transferrin 
receptors in serum was compared. 
(d) The serum concentration of transferrin receptors in a group of newborn infants 
was studied in relationship to other parameters of iron metabolism. In the 
same patients the microheterogeneity of transferrin was evaluated. 
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2.1 Introduction 
In this chapter the techniques used in the experiments are described in detail. All 
reagents used were of analytical grade. Patient samples were taken \vith permission of 
thc patients. Parents agreed that their babies participatcd in the study. The study design 
was approved by the medical ethics committee of the hospital after the methods had 
been optimised during a pilot study. 
2.2 Flow cytometry 
Cellular charactetistics can be snldied by immunologicalnuu'ker analysis. During 
differentiation the antigenic structure of the cellular membrane changes. By the 
expression of a certain combination of antigens different cell types can be 
distinguished and cells can also be classified according to a particular differentiation 
stage. 
The antigenic structure of the cell membrane can be studied by the use of conventional 
antisera or monoclonal antibodies. In recent years rnonoclonal antibodies have been 
increasingly used. A 1110noclonal antibody raised against the antigen of interest is 
incubated with the cell. If the specific antigen is present on the cell membrane this 
antibody will bind to it. After a washing step to remove the excess of unbound 
antibody the bound antibody can be detected after addition of a t1uorescent label. This 
detection can be performed both by microscopy and flow cytometty. A classification 
system has been developed for the increasing number of lllonoclonal antibodies 
available during the last decades. During international workshops 1l10noclonal 
antibodies showing the same reaction pattern are grouped together in "clusters of 
differcntiation or designation" (CD). 
Many monoclonal antibodies are commercially available and attached directly to a 
fluorochrome. Different fluorochromes are available, fluoresccin isothiocyanate 
(FITC) and phycoerythrin (PE) bcing the most frequently used in t10w cytometly. 
Monoclonal antibodies that are not attached to a fluorochrome by the manufacnlrer 
(unconjugated antibodies) can be coupled to a t1uorochrome after binding of the 
antibody to the cellular antigen. These unconjugated antibodies are mainly used for the 
detection of antigens which arc weakly expressed. 
Multiple immunological staining techniques make it possible to study the concurrent 
expression of two different antigens in one cell type. The easiest way is to combine 
two fluorochrome conjugated antibodies. These antibodies can be mixed and 
incubated with the cell suspension. Recent developments in tlow cytometty and 
especially in the software have made the concurrent use of up to 5 fluorochromes in 
onc experiment possible. 
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2.2.1 The flow cytometer 
A flow cytometer is an instrument developed to analyse cell samples. The FacStarpl" 
(Becton Dickinson, USA) used in the experiments in this thesis is equipped with a 100 
m W water cooled argon laser light source which provides monochromatic light at 488 
nm and a low power helium-neon laser providing a monochromatic light beam at 633 
nm. A schematic diagram of the instrument is given in figure 2.1. Cells in a 
suspension pass in a laminar non turbulent stream through the nozzle in an open air 
measurement region. The sample tluid is centred into the nozzle by a pure laminar 
flow. This is achieved by forcing the sample fluid into a sheath fluid flowing under 
pressure slightly lower than that of the sample fluid. The laser beam is focused 
perpendicularly to the cell stream. Cells sequentially pass the laser beam light and are 
detected individually. 
Figure 2.1 - Diagrammatic representation of a dllallaserflow cytometer. 
," 
As the cells pass the laser beam, the light is scattered in ditferent directions. This 
scattered laser light is detected both at a low angle in the forward direction (forward 
33 
Chapter 2 
scatter signal, FSC) and at 90° (sideward scatter signal, SSC). The FSC signal depends 
primarily upon the volume of the cells, whereas the SSC signal is mainly determined 
by the internal organisation, cytoplasmic granularity, nuclear density and external cell 
structure (1,2). The FSC light and the SSC light are detected in detection devices such 
as a photodiode. Weak signals arc first amplified in a photomultiplier tube. The light 
signal is then converted into an electric signal directly proportional to the light signal. 
The electric signal can be analysed using commercially available software. The FSC 
and SSC signals of a certain cell suspension can be plotted in a diagram. In this 
diagram different cell populations can be distinguished, which makes the analysis of a 
selected cell population possible. 
As the cell suspension passes the laser light, fluoroehromes attached to the cell will be 
excited by the laser light. These fluoroehromes will emit fluorescence light. The 
fluorescence light will be detected in photomultiplier (PM) tubes in the same way as 
the scattered light. The magnitude of the electric signal is directly proportional to the 
number of fluorescent molecules which have bound to the cell. Different 
fluorochromes emit light with different wavelengths. The detection of these different 
wavelengths is pelformed by splitting the lightbeam by dichroic mirrors. The 
appropriate wavelength collected in each PM tube is selected by the filter system 
placed in front of the PM tube. This filter system makes it possible to easily apply new 
fluorescent labels. The measurement of the electric signal from a tluorescent label is 
performed with logarithmic amplification. The sensitivity of the light detection device 
depends on the voltage applied and on the amplifier gain setting. These settings have 
to be checked daily by the use of standard particles sllch as fluorescence beads and 
adjusted if necessary. These instfluilent settings can influence the results. For 
quantitative analysis the use of standard beads carrying well defined numbers of 
fluorochromes per bead is obligatory. 
The light emitted from the fluoroehromes can be plotted in a dual parameter dot plot 
as has been described for the FSC and SSC signal (figure 2.2). This can be done for all 
the cells or one population can be selected from the FSC/SSC diagram. The data 
gained from these diagrams can be analysed using the instrument software. 
The FaeStar"" flow cytometer is equipped with a cell sorting unit. This makes it 
possible to isolate certain ceUs for individual analysis. 
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2.2.2 Preparation of the cell suspension and cytospin slides 
Cells could be isolated for immunological marker analysis by density centrifugation 
using a commercially available density gradient (Lymphoprep, Nycomed Oslo). Bone 
malTOW aspirations were obtained from the iliac crest or from the sternum. The bone 
marrow cells were drawn in citrate to prevent clotting: 1 ml of sodium citrate (3.8%, 
w/v) was added to 3 ml of bone malTOW aspirate. The bone marrow aspirate was then 
diluted with Isoton Diluid Azid Free (Baker) and 6 ml of this mixture was carefully 
layered over 3 ml of lymphoprep. This mixture was centrifuged for 15 minutes at a 
force of 800 g for 20 minutes at foam temperature in a swing out rotor. The 
mononuclear cells formed a distinct band at the sample/medium interface and could be 
removed using a Pasteur pipette. The cells were then washed twice with Isoton Diluid 
Azid Free containing 0.5% bovine serum albumin (w/v) and 0.05 % sodium azide 
(w/v) for 5 minutes at room temperature with a force of 400 g. For surface membrane 
analysis the cells were suspended in RPMIIFetal Calf Serum (10%, v/v) to a tinal 
concentration of 10 x 106/1. 
Figure 2.2 - Example of a two parameter dot plot. 
FL1-H'CD71'IOAl FITC ---) 
35 
Chapter 2 
Cells were suspended at a concentration of 10'-10' cells per ml in a protein-containing 
suspension. Two hundred III of this suspension were added to the sample chamber 
(Shandon,UK) which had been prespun with one drop of buffered saline. The sample 
chamber was placed in a cytospin centrifuge (Cytospin 3, Shandon,UK) and the cells 
were spun for 5 minutes at 200 g. The sample slidcs were removed from the centrifuge 
and allowed to air-dry. 
2.2.3 Detection of transferrin receptors on erythroblasts 
To study the antigenie structure of the cells in the suspension the cells were incubated 
with sets of two monoclonal antibodies. These antibodies were conjugated with FITC 
and PE respectively for 30 minutes at 4 QC at a concentration recommended by the 
manufacturer. MoAbs used were LCA (CD 45), LeuM3 (CD 14), Leu4 (CD 3), Leul2 
(CD 19), LeuM9 (CD 33) (Becton-Diekinson, San Jose, CA, USA); OKM5 (CD 36) 
(Ortho Diagnostic Systems, Raritan, NI, USA); IOA71 (CD 71) and GLY-A 
(Immunotech, USA). Control mouse Ig's (IgGI and JgG2a) were also purchased from 
Becton-Diekinson, USA. 
The cells were analysed on a FacStarp1us flow cytometer equipped with Lysis II 
software (Beekton-Diekinson, USA). The nucleated population was gated on a 
two-parameter forward light scatter and 90° light scatter cytogram. 
The percentage of erythroblasts expressing the surface antigen of interest (CD 71) was 
determined from a dual parameter dot plot (GL Y -A-FITCfCD 71-PE). To quantify the 
mean fluorescence intensity Quantum 25 fluorescence beads (kindly provided by 
Becton-Dickinson, USA) were used as a standard. Beads with 0 - 19.0 X 10' molecules 
of equivalent soluble fluorochrome (MESF) per bead were analysed on the flow 
cytometer. Each bead had its own fluorescence intensity which could be seen in a 
histogram (figure 2.3). By plotting the mean channel of fluorescence intensity for 
every bead, a standard curve could be drawn. The mean fluorescence intensity of 
different antibodies could be read as MESF from the standard curve by use of the 
mean channel of fluorescence intensity in the histogram. 
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Figure 2.3 - Example of standard beads rUIl on ajlow cytometer. By plotting the meall 
jluorescence cl/allnelnumber agaillst the given lvlESF a standard curve call be drawn. 
Determining the MESF of CD 71 on GL Y -A positive cells gave information on the 
number of transferrin receptors on el)lthroblasts of different patients. 
2.3 Preparation of bone marrow films 
Bone marrow aspirations were taken from the sternum or the iliac crest. The cells were 
drawn in citrate to prevent clotting and to make illlmunologicalmarker analysis 
possible. 
The preparation of bone marrow films was only satisfactory when both free marrow 
cells and marrow particles could be identified in a stained film. Preparations of 
marrow cells were made by isolating the marrow particles. Films were made by 
smearing out the particles between two slides under slight pressure. Care had to be 
taken since excessive pressure could cause disruption and distortion of the cells. 
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2.4 Staining methods for bone marrow films 
Bone marrow films were air dried before staining. From all patients three slides were 
stained with May Grlinwald-Giemsa and one slide was stained with the Prussian blue 
stain for iron. All slides were viewed by a panel of trained morphologists. 
2.4.1 May Griinwald-Giemsa 
Films should be stained as soon as they are dried in the air. Bone marrow films were 
fixed in methanol (Merck, Germany) for 5 minutes. The films were transferred to a 
staining jar containing diluted May Gliinwald's stain: 10.0 ml of buffer A, containing 
9.078 g KH,PO, in 1000 ml water was mixed with lOA ml of buffer B containing 
11.876 g Na,HPO,.2H,o in 1000 ml water and water was added to 500 m1. Twenty 
five ml of May Griinwald stain (Merck, Germany) was diluted with 25 ml of this 
buffer. The pH was measured and if necessary adjusted between 6.9 and 7.1. 
After the films had been allowed to stain for 3 minutes they were transfell'ed to a 
staining jar containing Giemsa's stain (Merck, Germany) freshly diluted with 7 
volumes of distilled water. The films were left for 15 minutes and then washed with 
distilled water. Finally the films were dried and covered by a coverslip using Entallan 
(Merck, Germany) as a mounting medium. 
2.4.2 Prussian blue stain for iron 
Air dried films of bone marrow aspirates were fixed in methanol (Merck, GelTImny) 
for 5 minutes. The bone marrow slides were put in a staining jar containing potassium 
ferrocyanide in HCl. This was made by mixing equal volumes of a solution containing 
50 g K,{Fe(CN),}.3H,O in 1000 ml water and a solution containing 16.5 ml HCl, 
37%, in 1000 ml water. The slides were left in this staining solution for 5 minutes at 
37 QC in a microwave processor or 30 minutes at room temperature. 
The slides were then rinsed in water for 30 seconds and transferred to a staining jar 
containing a filtered Kernechtrot staining solution made by mixing 200 mg 
Kernechtrot (Merck, Germany) and 10 g aluminiumsulfate-18-hydrate in 200 1111 
water. After the slides had been allowed to stain for 3 minutes at 37 QC in a microwave 
processor or for 15 minutes at room temperature they were rinsed with water, dried 
and covered by a coverslip using Entallan (Merck, Germany) as a mounting medium. 
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2.4.3 Staining for erythroid cells 
Air dried cytospin slides or bone manow films were fixed in absolute methanol 
(Merck, Germany) for 5 minutes. The slides were placed in a staining jar containing 
O-dianisidine stain made by mixing five volumes of an 0.2% solution of O-dianisidine 
(Koch-Light, ) in absolute methanol, onc volume of a 30% hydrogen peroxide solution 
(BDH Chemicals, UK) and one volume of a I % sodium nitroferricyanide solution. 
The slides are incubated in this solution in the dark for ten minutes and rinsed in 
water. The air dried slides were then counterstained with May Griinwald-Giemsa. 
2.5 Soluble transferrin receptors in serum 
Soluble transferrin receptors could be identified by the use of an enzyme immunoassay 
based upon the double antibody sandwich method (16). For many years the purified 
transferrin receptor was not available, making the standardisation of the enzyme 
immunoassay complicated. Recently three test kits have appeared on the market for 
the determination of soluble transferrin receptors in serum or plasma. In chapter 4 
these test kits have been compared and a small clinical study has been described. 
As in every enzyme immunoassay the duration of the incubation steps was critical and 
accuracy of pipetting was essential for the reproducibility of the results. 
2.5.1 Principle of the test 
The reaction was performed in microwells that were precoated with a polyclonal 
antibody against the transferrin receptor. Plasma or serum samples were diluted and 
pipetted into the wells. Murine monoclonal antibodies with specific reactivity against 
the human transferrin receptor were added to the wells. This murine monoclonal 
antibody was conjugated to horseradish peroxidase (HRP) to make the reaction visible. 
During the incubation period the transferrin receptor in the sample bound to the 
polyclonal antibodies absorbed on the wells and the HRP-conjugated antibodies bound 
to the captured soluble transferrin receptors. The microwell plates were thereafter 
washed to remove any unbound transferrin receptor and excess of HRP conjugate. An 
enzyme substrate for the HRP was then added to the wells (chromogen TMB). The 
action of HRP formed a blue product during a second incubation period. To stop the 
enzyme-substrate reaction an acid solution was added to the wells. The blue product 
was then converted into a yellow colour. The intensity of the yellow colour was 
directly related to the amount of bound transferrin receptor in the well, which was 
directly proportional to the concentration of soluble transferrin receptors in the 
sample. 
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2.5.2 Test procedure 
Three commercial tests were available on the market: the RAMCO assay distributed 
by DPC, Apeldoorn, The Netherlands, the Eurogenetics assay distributed by 
Eurogenetics, Tessenderlo, Belgium and the Orion test kit distributed by Imphos, 
Amersfoort, The Netherlands. In the following section the differences between the 
assay procedures are indicated. Once the assay has been started, all steps should be 
completed without intermption. 
2.5.2.1 Sample preparatioll 
One of thc major differences between the three assays is the sample preparation. The 
Orion assay is the only assay which does not require predilution of the serum samples. 
In the RAMCO assay samples have to be prediluted I: 100 in sample diluent whereas 
in the Eurogeneties assay a dilution of I: 10 is required. In the RAMCO test kit the 
standards are provided at the required concentrations. For the Eurogenetics assay the 
standards have to be prediluted I: 10 as well. In the Orion test kit sTfR standards 
require reconstitution in distilled water. 
2.5.2.2 The allalysis 
The prepared samples and standards wcre pipetted in individual wells in duplicate 
(100 rll in Eurogenetics, 50 rll in RAMCO and 20 pI in Orion). Two hundred rll of 
buffer was added to the wells in the Orion assay. In the RAMCO assay 150 rll of 
HRP-conjugate was added immcdiately. In the Eurogenetics and Orion assays the 
HRP-conjugate was added after incubation of the sample in the wells in a moist 
atmosphere at room temperature: for 30 minutes (Eurogenetics) or I hour (Orion). 
After this incubation the plates were washed 4-5 times and the HRP-eonjugate was 
added to the wells (100 pI in Eurogenetics and 200 rll in Orion). After the addition of 
the HRP-conjugate the microtiter strips were incubated at room temperature in a moist 
atmosphere (2 hours in RAM CO, onc hour in Orion and 30 minutes in Eurogenetics). 
After the incubation the strips were washed and freshly prepared substrate solution 
was added. Finally the strips were incubated for 30 (RAMCO and Orion) or 20 
(Eurogenetics) minutes at room temperature. The colour reaction was stoppcd by the 
addition of 50 r" stopping solution. The absorbency of each well was read at 450 nm 
in a microplate rcader which was blanked with 200 pI of substrate solution and 50 rll 
of stop solution in the RAMCO assay. 
2.5.2.3 Results 
The average absorbency of each standard was calculated and plotted against the 
corresponding soluble transferrin receptor concentration (UIl in Eurogenetics) and a 
standard curve could be drawn. The average absorbency of each patient sample was 
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calculated and the concentration of soluble transferrin receptors could be read from the 
standmd curve. These calculations could easily be performed by the use of computer 
programs which were commercially available. 
2.5.3 Precautions and interactions 
The kit had to be stored at 2-8 "C and reagents should be stored at this temperature as 
soon as possible after the completion of the assay. For the Eurogenetics assay the 
maximum number of strips in one run was limited to six. The reason for this was the 
short incubation time. 
Human serum or plasma could be used for the soluble transfelTin receptor 
measurements. No influence on the test results had been observed with anticoagulants 
as long as there is no dilution of the sample. Samples could be stored at 2-8 "C for a 
few days (7 for the RAMCO assay) or frozen at -20 "C for a longer time (6 months for 
the RAMCO assay). To avoid damage to the protein repeated freezing and thawing of 
the samples should be avoided. 
Haemolysis ought to be prevented although for the RAMCO assay it has been claimed 
that moderate haemolysis does not interfere with the test. 
2.6 Serum concentrations of ferritin and total iron 
The concentration of ferritin in serum was determined using an Irn" bench-top 
immunoassay system (Abbott. USA) (17). This system combines two assay 
technologies in one instrument; thc Microparticlc Enzyme Immunoassay (MEIA) ancl 
the Fluorescence polarisation immunoassay. The first method was used to measure of 
the scrum concentration of ferritin. 
The reaction was run in a j\'IEIA cell, which served as the solid phase element. The 
MEIA cells were loaded onto a carousel and inserted into thc analyser. The serum 
sample (150 Ill) was pipetted into the outermost well of the cell. The test specific 
reagent pack, which contains the antibody coated latex micro particles, was inserted 
into the system. The different assay components were automatically pipetted into the 
reaction well. After incubation, the reaction mixture was transferred to the glass fibre 
matrix. The unbound components were washed away and the alkaline 
phosphatase-Iabclcd conjugate was added followed by the addition of the fluorogenic 
substrate 4-mcthylumberrifyl phosphate. The resulting 4-methylumbelliferone was 
detected by a front-surface fluorometer. 
The total iron concentration in serum was determined on an AU 510 routine chemical 
analyser (Merck, Germany). 
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A serum aliquot was pipetted from a tube into a reaction vial in the instrument. Protein 
bound iron was released from transferrin by quanidinium chloride. The resulting free 
iron in the reaction vial was subsequently reduced to the ferrous (Fell) form by the 
action of ascorbic acid. The addition of ferrozin resulted in the formation of a reddish 
complex, which could be photometric ally analysed. The intensity of this colour was 
directly related to the total iron concentration in the sample. 
2.7 Identification of isotransferrins 
Different isotransferrins were identified in an analytical electrophoresis system as had 
been described by Van Noort et al. (18). 
Serum samples subjected to isoelectric focusing were first saturated with iron to 
occupy both iron binding sites. Complete saturation was ensured by mixing 50 fll of 
senun with 5 fll 0.6 nUllo1l1 of NaHCO, and 3 fll 10 mmolfl Fe(III) citrate. The 
samples were left to incubate for 1 hour at room temperature. 
The isoelectric focusing was performed on the Phast system (Pharmacia, Sweden) 
using an immobiline gel. To obtain a pH gradient between the electrodes of 5.0-6.0, a 
part of the immobiline DryPlate, pH 4-7 (Pharmacia, Sweden) was cut out to the same 
size as the Phast gel. Prior to isoelectric focusing the DryPlate was rehydrated by 
applying 1 ml 20% (v/v) glycerol on the surface of the gel for 90 minutes. To ensure 
an even heat transfer between the cooling plate and the gel, paraffin oil (50 fll) was 
applied between this plate and the gel backing. To obtain sharp bands without smears, 
pre-focusing was required. 
Prepared serum samples of 0.3 fll were applied to the gel in the Phast system. The 
instmment settings are summarised in table 2.1. 
Table 2.1 -instrument settings. 
sample applicator down at 
sample applicator up at 
sep xl 2,000 V 
sep xl 200 V 
sep xl 2,000 V 
1.5 mA 
0.3 mA 
1.5 mA 
x2 0 Vh 
x3 0 Vh 
1.5 W 15 'C 485 Vh 
0.3W 15 'C 15 Vh 
1.5 W 15 'C 1,800 Vh 
After focusing the gel was incubated with 100 fll rabbit anti-human transferrin at room 
temperature for 20 minutes. The gel was washed fot' 48 hout's in 0.15 M NaCl at 4 qc. 
This solution was changed several times. 
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The washed gels were stained. The gels were incubated for 20 minutes with 20% TCA 
and stained with Coomassie Brilliant Blue R (l g/I) at 50°C for 10 minutes according 
to the instructions described in the PhastSystem Users Manual (Pharmacia, Sweden). 
The gels were destained in 30% methanol (v/v), 10% acetic acid (v/v) at room 
temperature. 
Different transferrin bands were quantified in a densitometer (Ultroscan X laser, 
Pharmacia Sweden). The results were analysed using the Gelscan XL software 
(Pharmacia, Sweden). 
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3.1 Abstract 
The presence of transferrin receptors on erythroblasts in patients with iron deficiency, 
anaemia of chronic disease (ACD) and myelodysplastic syndrome (MDS) was studied 
by two colour analysis on a flow cytometer. CD 71 was nsed to quantify the number of 
transferrin receptors and GLY-A to identify erythroblasts. In cases of iron deficiency 
the number of transferrin receptors was increased on pmt of the erythroblasts thus 
facilitating iron uptake by the cells. In patients with ACD or MDS, a decrease of the 
number of transferrin receptors on elytluublasts was found. This leads to the 
conclusion that the ineffective response to iron therapy in cases of ACD and MDS can 
be explained by a decline of transferrin receptors on the red cells. 
3.2 Introduction 
Iron is essential for life. Every cell needs iron for metabolism and growth. Iron is 
delivered to cells by transfenin, an 80.000 Dalton glycoprotein which is capable of 
binding two molecules of iron per mol protein (I). Iron uptake is mediated by the 
transferrin receptor which is located on the cell membrane of most cells. After binding 
of transferrin to the receptol", the transfen-in-iron complex is taken up by the cell and 
iron release takes place. The apo-transfcnin-receptor complex leaves the cytoplasm 
and transferrin re-enters the senUll (2). 
Iron is needed by all cells, and even more so by developing red blood cells, which 
need extra iron for the production of haemoglobin. In ditferent conditions, abnormal 
iron uptake can be seen in bone malTOW aspirates by specific staining techniques. For 
example in patients suffering from anaemia of chronic disease (ACD), large amounts 
of iron can be seen in the macrophages of the Mononuclear Phagocyte System (MPS) 
while hardly any iron is taken up by the erytln·oblasts. These findings are opposite to 
morphological findings in myelodysplastic syndrome in which a normal iron content 
in the MPS is seen while iron may accumulate in the cI)lthroblasts. In these 
erytlu'oblasts thc iron is located in coarse dots around the nucleus while in normal 
cases iron appears as very fine dots in the cytoplasm. The question raises, whether the 
abnoffi131 iron metabolism in different conditions can partly be explained by an 
abnormal binding of transferrin to its receptor, or by abnormal steps in the intracellular 
metabolism. 
Much research has been done on the interaction of transferrin and its receptor in red 
blood cells. It has been established that in anaemia of chronic disorder iron uptal.e is 
decreased compared to normal individuals (3). In the myelodysplastic syndroEl<. 
(MDS), erythron transferrin uptake has found to be independent of plasma iron 
concentration and higher than in normal individuals (4). 
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Flow cytometry can be uscd to study the exprcssion of antigens on cell membranes 
like the presence of receptors and proteins. Monoclonal antibodics raised against these 
antigens are coupled to fluorochromes. Incubation of these monoclonal antibodies 
with the cells of interest will result in binding of the monoclonal antibody to its 
antigen giving a tluorescence signal which can be detected by a flow cytometer. 
In this study, flow cytometry was used to detect the presence of transferrin receptors 
on erythroblasts. A monoelonal antibody directed against the transferrin receptor 
(CD?I) was combined with an antibody specifIc for red blood cells active in synthesis 
of haemoglobin (Gly-A ). The intensity of the fluorescence signal is related to the 
number of fluorescence molecules binding to the cell. In this way the number of 
transferrin receptors on erythroblasts could be compared in different patients. 
Correction for day-ta-day instrument variation was performed by the use of 
tluorescence standard beads can)'ing a well defined number of fluorochromes on their 
surface. 
3.3 Materials and Methods 
All reagents used were of analytical grade. All samples were obtained with permission 
from the patient. 
3.3.1 Patients 
Bone marrow samples of patients from three groups with different forms of anaemia 
were studied. Bone marrow cells were obtained from the sternum or iliac crest. The 
diagnosis of ACD, iron deficiency or lvIDS was based on morphological criteria 
combined with clinical and chemical data. 
For the diagnosis of ACD patients were classified according to the clinical syndrome 
and chemical data. In all patients a decreased haemoglobin concentration was found 
(range 9-11 g/dl). The iron content in serum was low (range 2-11 pmol/l) and in all 
patients elevated ESR (> 45 mm) levels were found as a sign of an int1ammatory 
condition. In the bone marrow aspirate, the classic combination of high levels of 
stainable iron in the macrophages of the MPS and the absence of iron in erythroblasts 
was seen. 
Iron deficiency was defined by morphological criteria like microcytic anaemia and 
absence of iron in 1ll0lVhological staining techniques. In most patients a low 
haemoglobin concentration and low iron content in serum was found. In one patient 
however, the haemoglobin concentration was still normal. 
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The diagnosis of myelodysplastic syndrome was based on the morphological criteria 
by the latest French American British (FAB) classification (5). All bone marrow 
aspirates were viewed by a panel of morphologists. Patients diagnosed as chronic 
myelo-monocytic leukaemia (CMMOL) were excluded from the study, so were 
patients with refractory anaemia with excess of blasts in transformation (RAEBt). 
Bone mariOW samples of healthy volunteers were studied as normal controls. 
3.3.2 Immuno phenotyping 
Bone marrow samples were obtained after informed consent. Samples were drawn in a 
citrate solution to prevent clotting: I ml sodiumcitrate (3.8%, w/v) was added to 3 ml 
bone malTOW aspirate. Mononuclear cells were separated by density centrifugation 
using Lymphoprcp solution (Nycomed, Oslo). After being washed and centrifuged 
twice with Diluid (Baker), containing 0.5 % BSA (w/v) and 0.05 % NaN, (w/v), cells 
were suspended in RPMUfetal calf serum to a final concentration of 10 x 106 cells/!. 
Mononuclear cells were then incubated with two monoclonal antibodies conjugated 
with fluorescein isothiocyanate (FlTC) and phycoerythrin, respectively for 30 min at 
4°C at a concentration recommended by the manufacturer. The monoclonal antibodies 
used were LeA (CD 45), LeuM3 (CD 14), Leu4 (CD 3), Leul2 (CD 19), LeuM9 (CD 
33), all purchased from Becton-Dickinson, OKM5 (CD 36) purchased from Ortho, 
IOA71 (CD 71) and GL Y -A both purchased from Immunotcch. Control mouse Ig's 
(IgG I and IgG2a) were also purchased from Becton-Dickinson. The cells were 
analysed on a FacStarplus flow cytometer equipped with Lysis IT software 
(Beckton-Dickinson). The nucleated population was gated on a two-parameter forward 
light scatter and 90° light scatter cytogram. The percentage of erytln'oblasts expressing 
the surface antigen of interest (CD 71) was determined from a dual parameter dot plot 
(GL Y -A-FlTCICD 71-PE). To measure the mean fluorescence intensity Quantum 25 
fluorescence beads (kindly provided by Becton-Dickinson) were used as a standard. 
Beads with 0 - 19.0 X 10' molecules of equivalent soluble fluorochrome (MESF) per 
bead were analysed on the flow cytometer. In a histogram each bead can be seen as a 
peak having its maximum at another channel of fluorescence intensity. By plotting the 
mean channel and MESF for every bead, a standard curve was drawn. The mean 
fluorescence intensity of different antibodies was read as MESF from the standard 
curve by use of the mean channel of fluorescence intensity in the histogram. 
Determining the MESF of CD 71 on GL Y -A positive cells gave information on the 
number of transferrin receptors on erythroblasts of different patients. 
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3.3.3 Cryopreservation 
To a cell suspension containing 100 x 10' cells 5 ml of a cryopreservative was added 
dropwise at 4°C. The cryopreservative contains DMSO, RPM! and PCS (Gibco) in a 
final concentration of 10, 65 and 25% (w/v) respectively. DMSO is added as the last 
component after mixing with some of the RPM! and PCS. After adding the 
cryopreservatives the cells were transferred to -800C for at least 4 hours. The cells 
were then brought into a container with liquid nitrogen pending use. 
PCS was added to the thawing cells; cells were then spinned down at room 
temperature at 1,500 rpm for 5 min and washed twice with RPM! + 10% pcs. 
3.3.4 Staining procedures 
Bone marrow aspirates were examined on a slide stained with May Griinwald-Giemsa. 
Iron content is estimated by the Prussian blue reaction. 
Cytospin slides of bone marrow aspirates were stained before and after 
cryopreservation with a staining technique for erythroid cells (6). 
3.4 Results 
This paragraph describes the results obtained hom this study. The first section 
describes the freeze-thaw stability and in the second section the results of the flow 
cytometric experiments are given. 
3.4.1 Freeze-thaw stability 
To determine the freeze thaw stability of erythroblasts, cytospin preparations before 
and after freezing were analysed. These slides were stained with .May 
Griinwald-Giemsa and with a specific staining method for haemoglobin. With this last 
method, erythroblasts can be distinguished from other cells in a more accurate way as 
haemoglobin appears as a yellow brownish colour. In all cases we found a decreased 
number of el)ltluoblasts on the slides after thawing compared to the original slide 
(table 3.1). 
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Table 3.1 - Relative IIlllllber of elythrob/asts b~f()re alld cifter/reezillg. 
sample before freezi ng after thawing 
number 
1 11 8 
2 8 2 
3 6 2 
To study the freeze-thaw stability of the transferrin receptor, the MESF in different 
samples was determined before and after freezing. The MESF per bead decreased after 
storage at -J96°C (table 3.2). 
Table 3.2 - Relative Ill/Ill bel' 0/ trall~ferrill reeeptors 011 erythrob/asts be/ore alld ciffer 
a standard cryopreservat;oll procedure. 
sample before after 
population MESF population MESF 
1 1 4.43 3 0.37 
1.37 
4.96 
2 2 1.05 1 1.62 
4.66 
3 J 5.01 1 2.54 
3.4.2 Transferrin receptors on erythroblasts 
Using fresh bone marrow cells, the intensity of the fluorescence signal for CD 71 
expressed as MESFlbead was measured on the erythroblasts in patients with anaemia 
of different aetiology. This method is an indirect way to estimate the number of 
transferrin receptors on the cells. 
Table 3.3-3.5 show the results for different patients. Table 3.6 gives the results for 
healthy volunteers. 
so 
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Table 3.3 - Relative Jlumber vftrallsferrin receptors 011 cl}'throblasts ill c({ses of A CD. 
sample diagnosis population MESF 
1 ACD 1 3.2 
2 ACD 2 2.17 
6.53 
3 ACD 1 1.67 
4 ACD 1 4.43 
5 ACD 1 3.33 
6 ACD 2 1.01 
3.79 
7 ACD 1 2.39 
8 ACD 1 2.65 
9 ACD 1 2.51 
10 ACD 1 2.72 
11 ACD 1 3.03 
12 ACD 1 4.91 
13 ACD 1 3.54 
14 ACD 1 3.44 
15 ACD 1 4.35 
Table 3.4 - Relative 1lumber DJ trallsferrin receptors 011 elythroblasts ill cases of iron 
deficiency. 
sample diagnosis population MESF 
1 iron deficiency 3 3.31 
6.43 
11.88 
2 iron deficiency 2 0.27 
9.7 
3 iron deficiency 3 3.53 
7.09 
12.28 
4 iron deficiency 1 8.16 
5 iron deficiency 2 2.29 
8.78 
6 iron deficiency 2 1.97 
10.67 
7 latent iron 1 6.31 
del. 
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Table 3.5 - Relative number of trallsferrin receptors all cl),fhroblasts ill J\lf DS. 
sample diagnosis population MESF 
1 RA 1 3.22 
2 RAEB 3 0.57 
1.31 
3.46 
3 RA 2 1.41 
5.03 
4 RA 1 2.61 
5 RA 1 2.61 
6 RARS 1 2.51 
7 RARS 2 1.08 
5.49 
8 RAEB 1 3.34 
9 RARS 1 4.2 
10 RA 1 1.65 
11 RARS 1 1.02 
12 RA 1 1.09 
Tllhle 3.6 - Number oftrallsferrill receptors 011 el),throblasts expressed as kfESFlbead 
illlzealthy volu11feers. 
sample diagnosis population MESF 
1 volunteer 1 6 
2 volunteer 1 5.65 
3 volunteer 1 5.87 
4 volunteer 1 5.25 
5 volunteer 1 5.2 
In some cases more than one population of cells could be gated expressing both the 
transferrin reccptor as well as GL Y -A (figure 3.1). The difference between these 
populations was the fluorescence intensity for CD 71, while the signal for GL Y -A was 
constant. 
In patients with iron deficiency more than one group of cells could be defined in every 
patient, part of the cells having a very high expression of CD 71 while the remaining 
cells usually showed normal expression. 
In patients with anaemia of chronic disease and myelodysplastic syndrome, the 
fluorescence intensity in all cells was below normal values. In some cases an extra 
population was seen with an extremely low expression of CD 71. 
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Figure 3.1 - EXllmple of a two-parameter dot plot ill a patiem, llote: the two 
l'oplIlations of' GLY-A and CD 71 double-positive cells in the IIpper right quadrant. 
FLI-H'-Cl)71110Al FlTe -) 
3.5 Discussion 
Iron is one of the essential elements in the human body. All cells need iron for growth 
and metabolism. tvIuch research has been done on the interaction of the 
transferrin-iron complex and the transferrin receptor on different cell types. The 
erythroblast has been the cell of interest in many studies, since el)lthroblasts require 
iron for metabolism as well as for haemoglobin synthesis. Shortage of iron causes 
anaemia since iron is not available for incorporation into haemoglobin. In some types 
of anaemia the role of iron is less clear. Research has been done on the in vitro uptake 
of iron into erythroblasts of patients with ACD and i'vIDS. 
Recent progress in flow cytometry and the development of neW monoclonal antibodies 
make it possible to study the number of transferrin reeeptars on different eell types 
and in different conditions. In this study, the expression of transferrin reeeptors on 
erythroblasts was studied by the use of two monoelonal antibodies: CD 71 for the 
detection of the transferrin reeeptor and GL Y -A to define cry throb lasts in the bone 
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marrow samples. Cells which were reacting with both monoclonal antibodies were the 
cells of interest, as they are the erythroblasts active in haemoglobin synthesis and 
expressing tansfelTin receptors on its membrane. The number of transferrin receptors 
per cell Was quantified using a standard curve derived from the fluorescence intensity 
of standard beads. The value read from the standard curve is directly related to the 
number of transfelTin receptors on the erythroblast. 
In this study, different groups of patients were compared. A constant MESFlbead has 
been found in healthy volunteers. In these normal cases only one well-defined 
population of GL Y-A and CD 71 double-positive cells was found. It seems that in 
normal cases the number of transferrin receptors on erythroblasts is within very 
nanDW limits, not only within the same sample but also between various persons. In 
patients with anaemia more variation was seen. In most patients, irrespective the cause 
of the anaemia, more than one group of erythroblasts can be seen carrying different 
numbers of transferrin receptors on the membrane. In cases of iron deficiency 
increased numbers of transferrin receptors on the cell membrane were found in at least 
part of the cells. This can be easily explained as an adaptation of the body to the state 
of iron deficiency. Increasing the number of transferrin receptors on the membrane 
facilitates the uptake of iron by the cell. Patient number 7 was an interesting case. In 
this patient, iron deficiency was still in an early phase, anaemia had not developed yet, 
but the erythroblasts already carried an increased number of transferrin receptors. 
The findings in ACD and MDS arc less easy to be explained. MDS is a heterogeneous 
condition characterised by anaemia, dyshaematopoiesis and varying numbers of blasts. 
Following the FAB-classification chronic melo-monocytic leukaernia is included in 
MDS. However, it is not certain whether this condition is truly a myeloproliferative 
disorder. RAEB(t) is also included in MDS according to the FAB-classification, but it 
can be seen as an early stage of acute leukaemia. Both patients diagnosed as chronic 
myelo-monocytic leukaemia and RAEB(t) were excluded from this study. All MDS 
patients in our study had in common a low haemoglobin concentration and abundant 
coarse dots in the Prussian blue iron stain. Some patients showed classic ringed 
sideroblasts. All patients exhibited less of transfelTin receptors on erythroblasts than 
healthy controls. On part of the cells, the transferrin receptor was almost completely 
lacking. These erythroblasts will not be able to take up iron from transferrin as 
effectively as 110nnal erythroblasts. This can contribute to the ineffective 
etythropoiesis in MDS and explains why in these patients iron supplement does not 
lead to a rise in haemoglobin concentration. Two patients were diagnosed as RAEB. 
No ditferencc was seen in CD 71 expression when compared to RA or RARS. 
However, two patients is only a small number, so more experiments have to be done 
before a final conclusion can be drawn. 
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Similar date were obtained in cases of ACD. It is proved that in cases of ACD iron 
uptake in vitro is impaired compared to healthy controls (3). In this study wc found 
that in all patients at least part of the elythroblasts express a very low number of 
transferrin receptors. This will lead to a lower uptake of iron from transferrin. In bone 
marrow samples of patients with ACD, abundant iron is seen in the macrophages of 
the MPS were it is stored. Iron is administrated routinely to many patients with ACD. 
This is not effective since the erythroblast can not take up the iron, so all iron is stored 
in the MPS leading to an iron overload in many cases. 
Bone marrow samples of patients arc not easy to obtain. MDS is a rare condition and 
for the diagnosis of ACD and iron deficiency usually no bone marrow sample is taken 
since the diagnosis can be made using other parameters. Therefore it would be 
interesting to study frozen cells so samples can be obtained from other hospitals as 
well. However, this study proved that not only erythroblasts but also the transfelTin 
receptor can be destroyed in a standard cryoprescrvation procedure. This means that 
studies on the interaction of transferrin and its receptor can only be done on fresh 
material. 
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4.1 Abstract 
In this study the analytic pelfonnances of recently introduced assays for soluble 
transferrin receptors in selum were tested. The Rameo transferrin assay was compared 
with the Eurogenetics assay. In a small clinical study serum samples of patients with 
anaemia of chronic disease, iron deficiency and myelodysplastic syndrome were 
analysed as well as sera obtained from healthy volunteers. 
In a limited study the Orion transferrin receptor assay was compared to the Ramco 
assay. This study included an analysis of the analytical peti'ormanees as well as a 
limited clinical study to compare the clinical usefulness of the different assays. 
The analytical performances of the Ramco and Orion assays were found to be 
acceptable. In the Eurogenetics test however, inter assay imprecision and the end of 
nlll drift were unacceptable high. 
We were able to confirm that in patients with uncomplicated iron deficiency the 
concentration of soluble transferrin receptors is higher than in healthy volunteers. In 
cases of anaemia of chronic and inflammatory disease the levels of soluble transferrin 
receptors in scrum are slightly, but not significantly, highcr than in normal subjects. 
Measurement of soluble transferrin receptors in serum provides a good differentiation 
between anaemia of chronic disease and iron deficiency. However it was also shown 
that the clinical conclusion drawn may dcpend on the test kit used, as result of a lack 
of standardisation. Fm' diagnosis and follow up of patients this is unacceptable. The 
time for international standardisation has come to make results in the follow up of 
individual patients as well as results derived from clinical studies comparable. 
4.2 Introduction 
Iron is one of the most important elements in the human body. It is essential for 
cellular growth and metabolism. However, an excess of iron can lead to intracellular 
damage to DNA and proteins by producing free radicals in combination with oxygen 
(I). To prevent damage from these radicals iron is transported complexed to 
transferrin. 
The transferrin receptor is a transmembrane protein present in all body cells (1,2). It 
consists of two identical domains. Each domain is capable of binding two molecules 
of transferrin. The affinity of the receptor for transferrin depends on the saturation of 
transferrin with iron and is especially high for completely saturated transferrin. The 
number of cellular transferrin receptors depends on the cell's need for iron. The 
production of the transfenin receptor is regulated on the level of RNA by the 
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intracellular iron content. Depending on this concentration either the iron storage 
protein ferritin or the transferrin receptor is produced. Various proteins, the so called 
iron binding proteins, can innuence these processes. An excess of iron binding to the 
iron responsive elements facilitates the translation of RNA coding for the ferritin 
molecule. In intracellular iron deficiency, a decreased binding of iron to these proteins 
will lead to the translation of that part of the RNA which codes for the transferrin 
receptor. 
Soluble transferrin receptors in serum are found ns n truncnted fmgment of 
transmembrane transferrin receptors (3,4). The level of soluble transferrin receptors is 
directly proportional to the total mass of tissue reeeptors (2). Since most of the tissue 
receptors can be found on erythroid precursor cells, the concentmtion of transferrin 
receptors in serum is directly proportional to erythroid activity (5). In cases of 
erythroid hyperplasia as in iron deficiency and haemolytic anaemia, the level of 
soluble transferrin receptors is mised. In cases of bone marrow aplasia the level is 
sharply reduced. 
Recently the concentmtion of soluble tmnsferrin receptors in serum has been 
postulated as a new quantity in the diagnosis of anaemia caused by iron defiCiency 
(5,6,7,8). A possible role for soluble transfelTin receptors in the differentiation of 
anaemia of chronic disease from iron deficiency could be expected and has been 
described (9,lD,II). 
In the present study, the analytical performances of recently introduced soluble 
transferrin assays were tested. Serum samples from patients with anaemia of chronic 
and inflammatory diseases, iron deficiency and myelodysplastic syndromes were 
analysed as well as sera obtained from healthy volunteers. A bone marrow aspirate 
was taken from every patient in order to establish the amount of stail1able iron, which 
serves as the gold standard for total body iron stores. 
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4.3 Materials and methods 
This paragraph describes the materials and methods used in these experiments. All 
reagents were of analytical grade. All serum and bone marrow samples were taken 
after informed consent. 
4.3.1 Materials 
4.3.1.1 Test procedure 
The Ramco transferrin reeeptor (TfR) kit was obtained from DPe, Apeldoorn, The 
Netherlands. The Eurogenctics assay was obtained from Eurogenetics, Tessenderlo, 
Belgium. The Orion assay was purchased from Imphos, Amersfoort, The Netherlands. 
All sTfR kits are enzyme inullunoassays (EIA) based upon the double antibody 
sandwich method. They differ from each other in dilution the samples and in 
incubation time. In the Ramco test samples arc prediluted lOO-fold and in the 
Eurogenetics assay IO-fold. In the Orion assay no predilution step is required. The 
incubation time in the Ramco and Orion tests is one hour and in the Eurogenetics test 
only 20 minutes. Results are expressed as kU/I in the Eurogenetics assay and in mg/l 
in the Ramco and Orion tests. 
The assay procedures were followed according to the instructions lj'om the 
manufacturers. 
4.3.1.2 Apparatus 
Precision pipettes: reference pipettes wcre used obtained from Eppendorff, Germany. 
Microplates were washed in a microtitration plate washer 1296-024 obtained from 
Wallac, Finland. 
Microtiter plates were analyscd in the microplate absorption photometer type ht II 
obtained from Anthos, Austria. 
4.3.1.3 Patiellls 
Serum samples and freshly drawn bone marrow aspirates of patients with 3 forms of 
anaemia wcre studied. Serum samples were stored at -80 QC until analysis. 
Bone marrow cells were obtained from the sternum or iliac crest and analysed 
immediately. The diagnosis of anaemia of chronic disorder, iron deficiency or 
myeJodyspJastic syndrome was based on morphological criteria combined with clinical 
and chemical data. 
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For the diagnosis of anaemia of chronic disorder (17 patients), patients were classified 
based on the clinical syndrome combined with:-
(a) a low haemoglobin concentration; 
(b) a low iron content in serum; 
(c) the classic combination in bone marrow aspirates of high levels of stainable 
iron in the macrophages of the MPS and the absence of iron in erythroblasts. 
Iron deficiency (10 cases) was defined by the combination of:-
(a) a low haemoglobin concentration, low iron content in scrum; 
(b) a low ferritin concentration; 
(c) morphological criteria like microcytic anaemia and absence of bone marrow 
iron in morphological staining techniques. 
The diagnosis of myelodysplastic syndrome (10 cases) was based on the 
morphological criteria by the latest French American British (FAB) classification (12). 
All bone marrow aspirates were judged by a panel of trained morphologists. Patients 
diagnosed with chronic myelo-monocytic leukaemia were excluded from the study, as 
well as patients with refractory anaemia with excess of blasts in transformation 
(RAEBt). 
Serum samples with a concentration of soluble transferrin receptars ranging from 
2.6-28 mgll in the Ramco assay were selected to test the clinical value of the Grion 
assay. All samples wcre re-analysed with both assays simultaneously. 
Scrum samples from 62 healthy volunteers were taken as normal controls. 
4.3.1.4 Staining procedures 
Bone marrow aspirates were examined on a slidc stained with Nfay Griinwald-Gicmsa. 
Iron content was estimated by the Prussian blue reaction. 
4.3.1.5 Statistics 
For statistical analysis a Student-test was perfOlmed. 
Regression analysis according to Bablock and Passing was pelformed using 
commercial software Eval-kit 3.1, CKCHL, Elisabeth Ziekcnhuis, Tilburg, The 
Netherlands. 
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4.3.2 Methods 
4.3.2.1 intra assay imprecision 
To determine the intra assay imprecision ten replicate measurements on serum 
samples were performed. 
4.3.2.2 Illter assay imprecisio1l 
Duplicate measurements on 3 senUl1 samples were performed in order to determine the 
intra assay imprecision. Each sample was analysed in five different assays over a 
period of five weeks. Each serum was divided in five aliquots before freezing to 
prevent freeze-thaw instability of the receptor. 
The inter assay imprecision of the Orion test kit was limited to duplicate 
measurements of 2 samples. Each sample was analysed in two different assays on the 
same day. Additionally the end of run drift was determined by analysing the same 2 
samples in the first wells as well as in the last wells of the microplate in two runs. 
Additionally the end of run drift was determined by analysing the same samples in the 
first wells as well as in the last wells of the microplate or in the last wells of six strips 
(Eurogenetics). 
4.3.2.3 Analytical sensitivity 
The zero standard was determined ten tiI1les along with the set of standards and 
controls. The lowest detectable transfenin receptor concentration was considered as 
the mean extinction of the zero standard plus two times the standard deviation. 
4.3.2.4 Assay linearity 
Serial dilutions of serum samples were measured. Serum samples were diluted with 
zero standard from I-fold to lO-fold. 
4.3.2.5 Method comparison 
Regression analysis was performed according to the procedure described by Passing 
and Bablock (13). 
4.3.2.6 Reference willies 
To find the normal values, 62 sera of healthy volunteers were analysed. The normal 
range was defined as the mean value ± 2 SD. 
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4.4 Results 
This section describes the results obtained from this study. In the first part the 
analytical perfonnances of all tests are described. The second part gives the results of 
the clinical study. 
4.4.1 Analytical performances 
4.4.1.1 Illfra assay imprecisioll 
In the three samples a mean serum transferrin receptor concentration of 1.9 mg/l, 6.2 
mg/l and 12.1 mg/l was found. The Orion assay was tested with eight samples with a 
mean transferrin receptor concentration ranging from 0.6 - 9.0 mg/l. 
Using these samples an intra assay imprecision of respectively 5.4%, 3.5% and 4.5% 
was found in the Ramco assay. In the Eurogenetics assay a variability of respectively 
4.7%, 7.4% and 11.1 % was found. The intra-assay imprecision in the Orion assay 
ranged from 3.9% to 6.1 %. 
4.4.1.2 lllferassay imprecision 
Three serum samples were used with a mean concentration of soluble transferrin 
receptors of 2.3 lllg/l, 6.0 lllg/l and 12.0 lllg/lrespectively. 
Using these samples, an inter assay imprecision of9.0%, 5.5% and 5.4% was found in 
the Ramco assay. In the Eurogenetics assay these values were 23.7%, 14.7% and 
19.5%. 
A mean end of run drift of 4.1 %,5.5% and 10.6% in the Ramco assay and a mean end 
of run drift of 13.9%, 10.9% and 14.4% in the Eurogenetics assay were found. In 
individual runs the end of run drift after 6 strips could rise up to 24% in the 
Eurogenetics assay. 
In the Orion assay the inter assay imprecision was 4.0% and 6.2% and no end of run 
drift was found. 
4.4.1.3 Analytical sensitivity 
The detection limits ofTfR are 0.2 mg/l in the Ramco assay and 31 kU/l in the 
Eurogenetics assay. 
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4.4.1.4 Assay linearity 
In the Ramco assay the recovery after dilution was 108% for I-fold to 10-fold diluted 
samples. In Eurogenetics the recovery was progressive from 114% in an I-fold to 
126% in a IO-fold dilution. 
4.4.1.5 Method comparison 
In regression analysis a linear correlation between the Ramco and Eurogenetics tests 
was found, r=0.863 (figure 4.1). A linear correlation was also found between the 
Ramco and the Orion test (r=0.700). 
Figure 4.1 - Atlet/wd comparison by regression analysis pe/formed according to 
Passing and Bab!ock. Results of the Ramco assay are expressed as pg/ml x lOO, ill the 
Eurogcnetics assay as V/m!. 
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4.4.2 Clinical significance 
For the Ramco assay we found a normal range of 4.94 +/- 1.64 mg/I, for the Orion 
assay 3.1 - 4.5 mg/l. In the Eurogenetics assay the normal range was 351 +/- 200 U/ml. 
With Ramco assay 17 sera were analysed of patients with anaemia of chronic and 
inflammatory diseases, 10 sera of patients with proven iron deficiency and 10 sera of 
patients with MDS. Results are shown in table 4.1. 
In iron deficiency the mean transfenin receptor concentration was significantly higher 
than in normal subjects. In ACD the mean concentration was significantly lower than 
in iron deficiency and differs not significantly from normal subjects. In MDS the 
range was very wide but excluding the two most extreme values resulted in a mean 
concentration which was not significantly different from normal subjects. 
Table 4.1 - Serum fran\/errin recep/ors ill normal subjects and ill patients with iroll 
deficiency, myelodysplastic syndrome and anaemia a/chronic and iI{tlammatOl), 
disease. 
diagnosis cases transferrin range p·value 
receptor mg/l 
healthy 62 4.94 ± 0.82 3.4, 7.0 ......... 
volunteers 
iron deficiency 10 12.23±2.03 10.0· 15.8 < 0.01 
myelodysplastic 10 11.61±11.63 4.2· >40 < 0.01 
syndromes 
anaemia of 17 5.84 ± 1.95 3.0·8.7 < 0.01 
chronic disease 
The clinical value of the Orion test kit was tested by analysing 38 serum samples with 
both the Orion and the Ramco test kits. The upper limit of the reference interval was 
exceeded in 22 of 38 patients using the Ramco assay. However, the upper reference 
value was exceeded in all patients when lIsing the Orion test kit, leading to a different 
clinical conclusion in 16 cases. The deviation which was found was not consistent: in 
10 cases the concentration of sTfR in the Ramco assay exceeded the value found by 
the Orion assay, while in 16 cases the opposite was found. In 12 cases both values 
exceeded 10 mg/l. Since the highest standard in the Orion test kit is 10 mg/l, the true 
value of these samples could not be measured with this test kit without predilution. 
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4.5 Discussion 
The analytical performances of three commercial available assays for soluble 
transferrin receptors in serum were studied. In addition the clinical significance of the 
results was assessed. 
The test kits distributed by Eurogenetics and Olion were easier to use when compared 
to the Ramco assay but the analytical performances of the Eurogenetics assay were 
unacceptable. The combination of a high inter assay imprecision and a high end of run 
drift makes the assay useless in a routine laboratory, although increasing the 
incubation time to one hour and increasing the dilution of the samples might improve 
the results. The manufacturer recommends to test only 6 strips in one nlll. However an 
cnd of run drift of 24% within the first 6 strips was still found. Analysing only 6 strips 
in one run makes the test much more expensive than the Ramco test because a 
standard curve has to be established in every run. 
The analytical pelformance of the Ramco and Orion assays were better. We found 
intra and inter assay imprecisions that were slightly higher or the same as those given 
by the manufacturer. 
The highest standard in the Orion assay has a concentration of 10 mgll, making it 
unsuitable for measuring samples which exceed 10 mg/l. Introducing an extra high 
level standard to the set of standards may solve this problem. 
Both the Ramco and the Orion test kit express their results inmgll, suggesting 
comparable results, but the results derived from both assays were not comparable. In 
16 out of 38 cases this led to a different clinical conclusion. In contrast, the 
Eurogenetics assay expresses the results in kU/I. In the past, standardisation of the 
soluble transferrin receptor assays has been problematic, because purified transfcrrin 
rcceptors were not available. The lowest standards in the Orion test kit are derived 
from pooled human serum, while the highest standard consists of purified placental 
transferrin receptor. The affinity of the monoclonal antibody can be different for 
receptors derived from different tissues. The set of standards in the Ramco test kit is 
composed of purified placental transferrin receptor. This guarantees a comparable 
affinity of the monoclonal antibody for every standard. 
The diagnosis of an uncomplicated iron deficiency is usually straightforward. Serum 
ferritin is a reliable blood constituent for predicting bone marrow iron stores. 
Prediction of the iron content in bone marrow from the ferritin concentration in serum 
is less reliable in inflammatory disease, in cancer and liver disease. In these cases 
sel1ll11 ferritin is often raised as a result of the acute-phase reaction. Serum ferritin 
parallels other proteins such as C-reactive in the acute-phase reaction. Often a bone 
marrow aspirate has to be taken to establish the diagnosis of anaemia of chronic 
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disease. Therefore it would be valuable to have a new quantity for the differentiation 
of iron deficiency from anaemia of chronic and inflammatory disease. It has been 
postulated that the soluble transferrin receptors in serum could be important in this 
differentiation (9). 
In earlier publications the concentration of sTIR has been found to be an important 
tool in the assessment of iron status. In this study we were able to confirm that in 
patients with uncomplicated iron deficiency the concentration of soluble transferrin 
receptors is significantly higher than that in healthy volunteers. In cases of anaemia of 
chronic and in!1ammatory disease the levels of soluble transferrin receptors in serum 
are slightly, but not significantly, higher than in normal subjects. By measuring soluble 
transferrin receptors in serum a good differentiation between anaemia of chronic 
disease and iron deficiency is possible. 
An other diagnostic problem is caused by anaemia as part of myelodysplastic 
syndromes. Myelodysplastic syndrome is a heterogeneous group of disorders in which 
anaemia is often the presenting symptom. In the early phases many patients receive 
iron to correct their haemoglobin concentration, leading to a delay in diagnosis and 
accumulation of iron in multiple organs. In this study soluble transferrin receptors in 
the sera of patients with myelodysplastic syndrome were analysed. The results varied 
enOlmously. In most patients normal levels were seen. However, some individual 
patients showed extremely elevated values, even far above the upper limit found in 
severe iron deficiency. These results indicate that in myelodysplastic syndrome 
investigation of the bone marrow is still required for diagnosis, and soluble serum 
transferrin receptor analysis is not helpful. 
In conclusion, the results in this study have shown that the analytical performances of 
the Ramco and Orion assays were acceptable, whereas those of the Eurogenetics assay 
were not. In the latter assay the inter assay imprecision and the end of n1l1 drift were 
unacceptable high. Using these commercial test kits the small clinical study confirms 
previously published data showing that soluble transferrin receptors are elevated in 
uncomplicated iron deficiency. IVleasuremcnt of the concentration of transferrin 
receptors in serum can help in the differentiation of subjects with anaemia of chronic 
and inflammatory disease from those with iron deficiency. In the diagnosis of 
myelodysplastic syndrome the soluble transferrin receptor concentration is of no help 
and a bone marrow aspiration is always required. However it was also shown that the 
conclusion drawn may depend on the test kit used, as result of a lack of 
standardisation. For diagnosis and follow up of patients this is unacceptable. The time 
for international standardisation has come to make results in the follow up of 
individual patients as well as results derived from clinical studies comparable. 
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5.1 Abstract 
The expression of transferrin receptors on the cell membrane of erythroblasts was 
analysed with flow cytometry in patients with different forms of anaemia. At the same 
time the concentration of soluble transfelTin reeeptors (sTiRs) was analysed in senun. 
It was shown that only in iron deficiency a high concentration of sTfRs in serum could 
be explained by an increased expression of transferrin receptors on the erythroblastic 
membrane. In anaemia of chronic disease and myelodysplasia a discrepancy between a 
low expression on the cell membrane and nonnal or elevated serum values was seen. 
From this study we conclude that the concentration of sTiRs in serum does not only 
depend on the expression of transfelTin receptors on the erythroblasts but also on the 
erythroid proliferation activity. 
5.2 Introduction 
Iron is a key element in cell mctabolism and growth in all cell types (I). Erytln·oid 
cells have a special requirement for iron due to the synthesis of haemoglobin. In 
serum, iron is transported complexed to transferrin, an 80 kDalton glycoprotein which 
is capable of binding two molecules of iron per transferrin molecule. The 
transfclTin-iron complex binds to the transferrin receptor on the cell membrane thereby 
making iron uptake possible (1,2). 
The transfenin receptor is a transmembrane protein present in all body cells. The 
number of transferrin receptors per cell depends on the requircment for iron and is 
regulated at the level of RNA (1). In intracellular iron deficiency transferrin receptors 
are produced, whereas in the state of intracellular iron overload the storage protcin 
ferritin comes to expression (3). The transferrin receptor can be detected on the cell 
membrane by flow cytometry by using the monoclonal antibody CD71. Using another 
monoclonal antibody for distinguishing different cell types, the presence of transferrin 
receptors on a special cell type can be studied. The combination of GL Y -A and CD 71 
gives information on the number of transferrin receptors on erythroid cells (4). 
In sel1lm soluble transferrin reeeptors (sTfR) can be found as truncated fragments of 
the intact cellular reeeptors. These fragments appear in scrum due to shedding or 
cleavage (2,5,6). The level of transferrin receptors in serum has been found to be 
directly proportional to the total amount of tissue reeeptors (2). Since the majority of 
tissue reeeptors can be found on erythroid cells, this is directly proportional to the 
erythroid mass. In cases of erythroid hyperplasia a rise in the levels of soluble 
transferrin reeeptors can be expected. This has been found to be true in iron deficiency 
and haemolytic anaemia (7,8,9,10). Likewise, in cases of bone marrow aplasia the 
level is sharply reduced. In patients with ineffective erythropoiesis, as in 
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myelodysplastic syndromes, a rise in the level of soluble transfelTin receptors could be 
expected because of the increase of the erythroid compartment. However this 
relationship has not been found (11,12). 
In the present paper we wish to describe the relationship between the expression of 
membrane bound transferrin receptors on erythroblasts and the level of sTfRs in 
SenlIl1. Soluble transferrin receptors in semm were quantified by an enzyme immune 
assay. The expression of membrane transferrin receptors was studied by tlow 
cytometry. 
5.3 Materials and Methods 
This paragraph gives an overview of the methods used in this study. All reagents were 
of analytical grade. All patients samples were obtained with permission. 
5.3.1 Patients 
Fresh bone malTOW aspirates were obtained from the sternum or iliac crest of 35 
patients who were refelTed to the laboratory for analytic tests of anaemia as well as 
from 4 healthy volunteers. A serum sample was taken at the same time or just before 
the bone marrow aspiration. Exclusion criteria were: blood transfusion just before the 
bone marrow punction and megaloblastic anaemia due to deficiency of vitamin B 12 or 
folic acid. All bone marrow aspirates were viewed by a panel of trained morphologists 
and repetitive counting of at least 500 cells were performed. 
Patients were classified based on morphological criteria combined with clinical and 
chemical data as anaemia of chronic disease (17), iron deficiency (10) or 
myelodysplastic syndrome (8). 
The diagnosis anaemia of chronic disease (ACD) was based on clinical and laboratory 
data. The laboratory data were a low haemoglobin concentration, low iron content in 
selUm and the classic combination in bone marrow aspirates of high levels of stainable 
iron in the macrophages of the MPS and the absence of iron in erythroblasts. 
Iron deficiency was diagnosed by the combination of low haemoglobin concentration, 
low iron content in serum and morphological criteria like microcytosis and absence of 
iron using morphological staining techniques. 
The diagnosis of myelodysplastic syndrome was based on the morphological criteria 
by the latest French American British (FAB) classification (13). In this study only 
patients with refractory anaemia (RA), RA with an excess of blasts (RAEB) and 
refractory anaemia with ring sideroblasts (RARS) were included. 
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All bonc marrow samples were analysed within 12 hours of aspiration. Serum samples 
were stored at -80 QC until they were analysed. 
5.3.2 Apparatus 
Flow cytometer: FacStar"" flow cytometer (Becton Dickinson, USA) was used to 
analyse the cells. This flow cytometer was equipped with Lysis 1I software. 
Precision pipettes: reference pipettes were obtained from Eppendorff, Germany. 
A microtitration plate washer 1296-024 obtained from Wallac, Finland was used for 
washing the microplates. 
Microplates were analysed in the microplate absorption photometer type ht H, Anthos 
Austria. 
5.3.3 Staining procedurcs 
Bone marrow aspirates were stained with the May GrUnwald-Giemsa stain and 
examined on a slide. 
Iron content was estimated by the Pmssian blue reaction. 
5.3.4 Soluble transfcrrin receptors in serum 
Soluble transferrin receptors in scrum were quantified with the Ramco transferrin 
receptor kit, an enzyme immunoassay which was purchased from DPC, Apeldoorn, 
The Netherlands. The assay procedure was performed according to the instructions of 
the manufacturer. 
5.3.5 Immuno phenotyping 
Three millilitres of bone marrow aspirate were drawn in 1 ml sodium citrate (3.8%, 
w/v) to prevent clotting. Mononuclear cells were isolated by density centrifugation 
using Lymphoprep solution (Nycomed, Oslo). Cells were suspended in RPMII foetal 
calf serum to a final concentration of 10 x 106 cells!l, after being washed twice with 
Diluid (Baker), containing 0.5 % BSA (w/v) and 0.05 % (w/v) NaN]' 
The mononuclear cells were then incubated with two monoclonal antibodies 
conjugated with fluorescein isothiocyanate and phycoerythrin respectively for 30 min 
at 4 QC at a concentration recommended by the manufacturer. Monoclonal antibodies 
used were LCA (CD 45), LeuM3 (CD 14), Leu4 (CD 3), Leul2 (CD 19), LeuM9 (CD 
33), all purchased from Becton-Dickinson, OKM5 (CD 36) purchased from Ortho, 
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lOA 71 (CD 71) and GL Y -A both purchased from Inlll1Unotech. Control mouse 
immune globulins (lgG I and IgG2a) were also purchased from Becton-Dickinson. 
The nucleated population was gated on a two-parameter forward light scatter and 90° 
light scatter cytogram, the percentage of erythroblasts expressing the surface antigen 
of interest (CD 71) was determined from a dual parameter dot plot (GLY-A-FlTCICD 
7 I-PE). 
Transferrin receptors on erythroblasts were quantified as described (4). A standard 
curve \vas derived by plotting the mean channel and the fluorescence intensity 
(expressed as MESF) for evelY bead of Quantum 25 fluorescence beads (kindly 
provided by Becton-Dickinson). Determining the MESF of CD 71 on GL Y-A positive 
cells gives information on the number of transferrin receptors on erythroblasts of 
different patients. 
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5.4 Results 
A reference range for sTfRs in semm was established by analysing sera of 62 healthy 
volunteers. The normal range was defined as the mean value ± 2 SD and was found to 
be 4.94 ± 1.64 mg/l. 
Figure 5.1 shows the results of the analysis of sTfRs in serum. From this diagram it 
can be seen that in iron deficiency the concentration of sTfRs in serum was increased 
above the upper limit of the reference range. inlvlDS normallcvels of sTfRs were 
found in most patients. In two cases values were found that were far above the upper 
limit of the test. In anaemia of chronic disease the level of sTtR in serum was slightly 
elevated in 6 out of 17 patients. 
Figure 5.1 - COllcentration of soluble Irml.~ferrill receptol"s ill serum ill healthy 
volullteers, iroll deficiency, anaemia (~r chronic disease aud myelody.\]}lasia. 
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Figure 5.2 shows the expression of transfen·in reeeptors on the erythroblastic 
membrane. In somc patients more than one population of cells could be identified 
showing different fluorescence intensity for CD 71. This reflects a difference in the 
number of transferrin receptors for these populations of cells (4). In all cases it was 
possible to identify onc major population which is indicated in figure 5.2. The 
expression of transferrin receptors on the crythroblastic membrane was increased in all 
cases of iron deficiency. In MDS the exprcssion of transferrin receptors on the cell 
membrane was sharply reduced in some of the patients and comparable to healthy 
volunteers in the remaining patients. In ACD the expression of transferrin receptors on 
the cell membrane was reduced in most patients. 
Figure 5.2 - ExpressioJl (~rtr{lllsferrill receptors Oil the elythrohlastic membrane ill 
hone marrow of healthy volunteers, irOll deficiency, anaemia of chronic disea,\'e and 
lllyelodysplasia, 
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5.5 Discussion 
Transferrin is onc of the most extensively studied proteins of the iron metabolism. It 
transports an clement essential for cell metabolism between the sites of absorption and 
storage and the sites of utilisation. The interaction of transferrin and the transferrin 
receptor is essential for the influx of iron into the cell. 
In earlier studies it was shown that in cell culture transferrin receptors are released 
from erythroid cells to the serum at the middle to late phases of maturation, mainly 
from polychromatic erythroblasts (14). In human sera sTIRs can be found as truncated 
fragments of membrane bound receptors. In many studies the relationship between the 
concentration of sTfRs has been analysed in relation to clinical conditions. The 
increased concentration in iron deficiency was found to be a useful parameter in 
differentiating it from anaemia of chronic disease (15). 
TransfelTin receptors can be found on the cell membrane in almost all cell types. 
However the concentration is highest on erytln'oid cells, since these cells not only 
require iron for metabolism but also for incorporation in haemoglobin. It is for this 
reason that the concentration of sTfRs in serum is mainly influenced by the expression 
of transferrin receptors on erythroid cells. On theoretical grounds it can be expected 
that the level of sTIRs in serum does not only depend upon the expression of 
transfenin reeeptors on individual cells but also on the total mass of erythroid cells. 
Evidence for this hypothesis can indirectly be gained from clinical studies. For 
example in bone marrow aplasia the level of sTfRs is decreased. In iron deficiency an 
increased expression of transferrin receptors on the cell membrane can be found, 
reflecting the increased requirement for iron by these cells (8,9). 
In this study the level of sTiRs in serum was analysed in different clinical conditions 
in relation to the expression of transferrin receptors on the erythroblastic cell 
membrane. A direct relationship between the expression of transferrin receptors on the 
erythroid membrane and the level of soluble receptors in serum was only found in iron 
deficiency. In this condition the increased expression of transferrin receptors on 
erythroblasts leads la a direct rise in the concentration of sTIRs in serum. 
In ACD the expression of transferrin receptors on erythroid cells is subnormal as well 
as the in vitro uptake of iron (4, \6). In this study in 6 out of 17 patients the level of 
sTfRs in serum was increased while the expression of transferrin receptors on the cell 
membrane was reduced in most patients. This can not be explained by an absolute 
increase of el)lthroid mass since bone marrow cellularity and el)'throid activity were 
within normal limits. A possible explanation could be an increased shedding of 
transferrin receptors from the cell membrane of maturating erythroid cells. 
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In patients with MDS normal levels of sTIRs lVere found in some sera whereas on the 
erytlnuid cell membrane the concentration of soluble transfelTin receptors was sharply 
reduced. This could be explained by an increased cellularity and erythroid hyperplasia 
in the bone marrow aspirations reflecting an abundant amount of ineffective 
erythropoietic cells carrying decreased numbers of transferrin rcceptors on the cell 
membrane. In two cases an extremely elevated concentration of sTtRs was found in 
serum. The expression of transferrin receptors on the cell membrane was extremely 
low in both patients. Examination of the bone marrow aspirations revealed an extreme 
bone marrow hyperplasia with an abundant erythroid mass. 
Recently, tests have been introduced for the detection of sTIRs in semm. These tests 
were brought into the market for the differentiation of iron deficiency from the 
anaemia of chronic disease. In this study the results in these tests were compared to the 
total erythroid activity and the expression of transferrin receptors on the erythroid cell 
membrane. 
In conclusion it was found that only in uncomplicated iron deficiency can the 
concentration of sTIRs be correlated with bone marrow parameters. However the 
diagnosis of an uncomplicated iron deficiency is usually straightforward and the 
concentration of sTIRs does not provide additional information. In all other conditions 
the relationship between the level of sTfRs and membrane bound receptors was less 
clear and was also dependent on the total erythroid mass. This makes the interpretation 
of the level of sTIRs in serum difficult and a matter of debate. 
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6.1 Abstract 
The concentration of soluble transferrin receptors in serum has proven to be a reliable 
predictor of iron status in adults. Its high sensitivity for iron deficiency combined with 
a small sample size (l0 Jil) makes it an interesting parameter for the assessment of 
iron stores in newborn infants. 
In the present study we investigated the usefulness of the concentration of soluble 
transferrin receptors in serum in the assessment of iron metabolism in the newborn. 
Infants born after an uncomplicated labour were comparcd to infants in the intensive 
care unit. The molecular stl11cture of transferrin was studied to obtain information 
upon the interaction between transferrin and its receptor. 
The concentration of soluble transfcnin receptors in serum was found to be elevated 
compared to nOll11al adults and independent of iron metabolism. The concentration of 
soluble transferrin reccptors did not correlate with serum iron and ferritin 
concentration. In contrast to what was found in other studies, no relationship could be 
demonstrated between soluble transferrin receptors and birth weight or gestational age. 
The molecular structure of transferrin in infants, showed a shift towards the less 
sialylated isotransferrins. 
6,2 Introduction 
Iron stores at birth have been shown to correlate velY well with iron stores at 6, 9 and 
12 months of age (I). In infants born at term the iron stores are usually sufficient for 
the first months of postnatal growth (2). Premature infants are more likely to develop 
iron deficiency anaemia since the total body iron at birth is lower than in full term 
infants. In addition, postnatal grO\vth is faster than in infants born at term and 
susceptibility to infections puts an extra demand on the iron reserve (3). Iron 
deficiency in infants can lead to several systemic abnormalities, anaemia often being 
the first (2). However, the most serious result of iron deficiency at an carly age is 
alteration in cognitive performance and motor development. Several studies have 
shown impaired mental and motor development of infants with iron deficiency 
compared to their pcers with normal iron status (2,4-6). 
Should the state of iron deficiency bc cured as soon as the diagnosis has been made, 
iron overload should be prevented as we11. Recent studies in newborn infants have 
shown that detectable levels of non-proteinbound iron can be found in up to 25% of 
healthy infants (7-9). Non-proteinbound iron is rapidly oxidised thereby possibly 
catalysing the conversion of 0, and Hp, into the highly reactive hydroxyl radical 
(10-14). 
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This ambiguous relationship of man with iron has proven the clinical importance of 
the assessment of iron status. In adults the serum ferritin concentration is the method 
of choice to estimate the iron stores. Recently the iron concentration of ferritin has 
been described to be a better indicator of iron reserve (15). In infants the erythrocyte 
ferritin concentration has been shown to be a reliable parameter of iron stores (16). 
However, all of these methods require large sample volumes, which makes them less 
useful in (premature) infants. 
The cellular uptake of iron is mediated by the transferrin receptor. Iron is brought to 
the cell complexed to transferrin. The affinity of the transferrin receptor for transferrin 
depends both on the pH and the iron saturation of transferrin. Apart from that, the 
microheterogeneity of transferrin may also play a role. 
Recently, the concentration of soluble transfelTin receptors in serum has proven to be a 
reliable predictor of iron status. This parameter has been shown to reflect the cellular 
need for iron and is elevated in cases of cellular iron deficiency (17-20). Its high 
sensitivity for iron deficiency combined with a small sample size (10 pi) makes it an 
interesting parameter for the assessment of iron stores in newborn infants. The aim of 
the present study was to investigate the usefulness of the concentration of soluble 
transferrin receptors in serum in the assessment of iron metabolism in the newborn. 
This parameter was studied in relation to serum ferritin concentration and serum iron 
concentration as well as in relation to parameters such as gestational age, birth weight 
and birth asphyxia. 
The transferrins arc a heterogeneous group of proteins sholVing different degrees of 
sialylation and galactosylation. Different forms of human transfelTin have been 
described in biological fluids. In serum from healthy individuals the tetra-sialo 
transferrin is the main component. Variation in the microheterogeneity pattern of 
transferrin can be found in several pathological conditions. A highly aberrant pattern 
has been described in children suffering from a rare syndrome dominated by 
neurological abnormalities (21). In scrum from these children the di- and a-sialo 
fractions are present in high concentrations. This syndrome is known as the 
carbohydrate-deficient glycoprotein syndrome. However, little is known about the 
sialylation pattern of transferrin during normal foetal development. In the present 
study the sialylation of transfcrrins was studied in a group of newborns. 
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6.3 Materials and Methods 
This section summarises the methods used in this study. All samples from the delivery 
room were transported to the laboratory as soon as possible. Parents agreed that their 
babies participated in the study. 
6.3.1 Patients 
The study population consisted of 133 infants, 9S healthy infants with a gestational 
age of 34 weeks or more born after uncomplicated labour and 35 infants with a 
gestational age ranging from 27 to 40 weeks who were admitted to the neonatal 
intensive care unit for prematurity or other neonatal complications such as birth 
asphyxia. Parents agreed that their baby participated in the study and the study design 
was approved by the medical ethics committee of the hospital. 
Neonatal blood was taken from the umbilical cord, just after clamping. Blood samples 
were centrifuged immediately and serum was stored at -80°C llntil analysis. In all 
samples the serum iron concentration and the concentration of soluble transferrin 
receptors was assayed. To limit the sample volume the ferritin concentration was only 
assayed in the samples taken from healthy infants. The micro heterogeneity pattern of 
transferrin was assayed in 10 healthy children. 
Intensive care patients were divided into a moderately asphyxiated group (n=15, 
arterial cord blood pH <= 7.1S) and a non asphyxiated group (n= IS, arterial cord 
blood pH > 7 .IS). Severely asphyxiated children were not included in the study. 
In addition, when blood was withdrawn from the patients in the neonatal intensive 
care unit for clinical purposes during the first 5 days of life a small additional sample 
was taken to study the day to day variation of the soluble transferrin receptor 
concentration. For this study repeated samples were taken from 20 patients. These 
blood samples were taken from an indwelling arterial catheter and the serum samples 
were also stored at -80°C until analysis. Patients receiving a blood transfusion in the 
first days of life were not included in the study. 
Serum samples were taken from 64 adult healthy volunteers to obtain the normal 
values for soluble transferrin receptors in adults. 
6.3.2 Test procedures 
All chemicals used were of analytical grade. 
Pi petting was performed with reference pipettes that were obtained from Eppendorff, 
Germany. 
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Soluble transferrin receptors in serum were quantified with the Ramco transfenin 
receptor assay. This is an enzyme immunoassay which was purchased from DPC, 
Apeldoorn, The Netherlands. The assay was performed according to the instructions of 
the manufacturer. A microtitration plate washer 1296-024 obtained from Wallac, 
Finland, was used for washing the plates and microplates were analysed in the 
microplate absorption photometer type ht, Anthos, Austria. 
The iron concentration of semm was assayed by means of the A U 510 analyser 
(Merck, Germany). 
Thc ferritin concentration was analysed on a IM, immune assay system (Abbot!, USA) 
using the ferritin assay which was also purchased from Abbott, USA. 
The blood gas analysis was performed on a ABL-SIO blood gas system. 
Transferrin microheterogeneity was snldied in 10 newborns born after an 
uncomplicated labour. Different transfenins were separated by analytical isoelectrlc 
focusing on an immobilinc gel (pH 4-7) in the PhastSystem as has becn described in 
detail in chapter 2. 
To prevent interference of incompletely iron-saturated transferrin with the test results, 
serum samples were saturated with iron before the analysis was performed: 50 fll of 
scrum was incubated with 2 pi 10 mmolll Fe(III)citrate and 2 pi O.S molll NaHCO,. 
6.3,3 Statistics 
The association between the concentration of soluble transferrin receptors in scrum 
and other variables was calculated using Spearman's rank coefficient of correlation. 
As the concentration of soluble transferrin receptors does not show a normal 
distribution a Mann-Whitney test was performed to study the difference between 
groups. 
All statistical analysis was peIiormed using commercial soft ware (SPSS, Chicago, 
Illinois). 
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6.4 Results 
Figure 6.1 shows the distribution of soluble transfelTin receptor concentration in serum 
for adults and newborns. Thc median concentration of soluble transferrin receptors 
found in the adult population was 4.90 mg/l (10th-90th percentile: 3.96-6.18 mg/l). In 
the group of newborn infants a median concentration of 9.25 mg/l (10th-90th 
percentile: 6.30-14.63 mg/l) was found, which is significantly higher than in adults (p 
< 0.0001). 
Figure 6.1 - Soluble transferrin receplor concentration distribution between adults 
and Jlewborns. 
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The concentration of soluble transferrin rcccptors in serum was studied in relation to 
cord blood pH as an indicator of asphyxia. The mcdian conccntration of soluble 
transferrin receptors in moderately asphyxiated children (cord blood pH <=7.18) was 
10.45 mgll (10th - 90th percentile: 5.83 - 14.21 mg/l). In the non asphyxiated group, 
(cord blood pH > 7.18) the median concentration of soluble transferrin receptors was 
9.10 mg/l (10th - 90th percentile: 6.30 - 15.04 mg/l). This difference was not 
significant (p = 0.424). The difference between the concentration of soluble transferrin 
receptors in serum in infants in intensive care and healthy children was 110t significant 
(p = 0.082). 
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The day to day variation in soluble transferrin receptors in 20 intensive care unit 
infants was studied during the first 5 days of life. The median concentration of soluble 
transfenin receptors on the (irst day of life was 10.40 mgll (10th - 90th percentile: 
4.50 - 16.70 mg/l). On the fifth day of life a median concentration of9.30 mg/l (lOth-
90th percentile: 2.7 - 15.2 mg/l) was found. This difference was not significant 
(p = 0.683). 
However, in individual patients a sharp decrease or increase Was noted (l0.7 and 12.2 
mg/l falling to 2.4 and 2.2 mgll respectively and 15.6 mg/l rising to 21.3 mgll). 
The concentration of soluble transferrin receptors in serum was studied in relation to 
two parameters of iron metabolism: the total iron concentration in serum (figure 6.2) 
and the concentration of ferritin in serum (figure 6.3). The serum concentrations of 
soluble transfelTin receptor and iron did not correlate (r = -0.068). Only a slight 
negative correlation could be seen for the concentration of soluble transferrin 
receptors in serum and the concentration of serum ferritin (r =- 0.380). 
Figure 6.2 - Relationship between the serum concentrations of soluble tran\ferrill 
receptors alld toted iroll. 
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Figure 6.3 - Relationship betweeulhe serum concentrations (?/"soluble Irall.~ferrin 
receplors and ferrilin. 
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The relationship between the concentration of soluble transferrin rcccptors in serum 
and gestational age is shown in figure 6.4. No direct relationship could be found 
between these two parameters (r = 0.04). The same was found for the concentration of 
soluble transferrin reeeptors in serum in relation to birth weight (figure 6.5, 
r = - 0.110). 
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Figure 6.4 - Concentration (~rsoll(ble tra11.~rerril1 receptors ill serum ill reiafiollto 
gestational nge. 
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Figure 6.5 - COllceJllratioll of soluble tra11.~lerriJ1 receptors ill serum in relation to 
birth weight. 
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Table 6.1 summarises the mean percentages for 6-,5-,4-,3-,2-,1- and O-sialo transferrin 
given as a percentage of the total amount of transferrin. Results are compared with the 
reference values for an adult population (lower row). As can be seen from this table 
the percentage of highly saturated transferrin in newbol11s is significantly lower 
compared to adult values especially the 5-, and 6- sialo transferrin. At the other end of 
the spectrum a-sialo and l-sialo transferrin can be detected in newborns, while in 
adults these fractions are undetectable. 
Table 6.1 - A'lean percentages of d(fferelll iso-forms (~f trlln~lerrill ill new/JOrns mul 
adlllts. 
patients 6-sialo 5·sialo 4-sialo 3·sialo 2-sialo l·sialo O-sialo 
newborns 3.1 13.8 65 9.1 4.2 3 1.9 
adults 5 20 63 9 3 nd nd 
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6.5 Discussion 
The transferrin receptor is a transmembrane glycoprotein which is involved in the 
cellular iron uptake. Transferrin receptors can be found on the cell membrane of 
almost all cell types but the expression on the cellmcmbrane is highest on rapidly 
proliferating cells. In scrum, fragments of these receptors can be found (22). The 
concentration of soluble transferrin receptors in serum has been shown to be directly 
influenced by the total amount of tissue receptors. In adults the erythropoietic cells are 
some of the most rapidly proliferating cells in the body and not only require iron for 
metabolism but also for incorporation into haemoglobin. It is for this reason that the 
concentration of soluble transferrin reccptors in serum is mainly influenced by the 
expression of transferrin receptors on erythroid cells. 
In foetal life, rapid cell proliferation and tissue growth is not only restricted to the 
erythropoietic cells in bone marrow. Therefore the concentration of soluble transferrin 
receptors in serum can be expected to depend upon the expression of transferrin 
receptors not only on erythropoietic cells but on all cell types. As a result, its 
concentration will be elevated compared to the adult population. In addition, the 
concentration of soluble transferrin receptors in scrum could be expected to depend 
upon gestational age or birth weight. In this study the concentration of soluble 
transferrin receptors in serum was indeed found to be significantly higher in infants 
compared to the adult population. However, no relationship could be demonstrated 
between the concentration of soluble transferrin receptors in serum and gestational age 
or birth weight. This is in contrast to what was reported from a recent study (23). In 
this study a relationship was described between the concentration of soluble transferrin 
receplors and gestational age. However, the patients used in both studies were not 
comparable. In the present study all samples were taken after birth so were comparable 
to each other. This is in contrast to the other study in which samples were obtained by 
different techniques. The pre term semm samples were taken by antenatal umbilical 
cord blood sampling from foetuses in a rather stable physiological condition while 
samples from full term infants were obtained after birth. This may lead to differences 
in sample composition making it difficult to interpret results. Apart from that, careful 
examination of the results in this previous study shows that only a slight correlation 
has been described between the concentration of soluble transferrin receptors and 
gestational age (I' ~ 0.366, P ~ 0.06) and the variation is high. The conclusion drawn 
from this study that the concentration of soluble transferrin receptors can be of use in 
the clinical assessment of growth retardation seems to be premature and can not be 
confirmed by our data. 
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In our study no difference in the concentration of soluble transferrin receptors could be 
demonstrated in the healthy population compared to their asphyxiated peers. This 
latter finding implicates that the concentration of soluble transferrin receptor in selUm, 
in contrast to the concentration of ferritin in serum does not response to acute perinatal 
distress. 
In recent clinical studies the concentration soluble transferrin rcccptors has shown to 
reflect the cellular need for iron and has proven to be a sensitive parameter to 
differentiate anaemia of chronic disease from iron deficiency. In the state of iron 
deficiency the concentration of soluble transfenin receptors is elevated and has been 
shown to be inversely related to the ferritin concentration and serum iron 
concentration (24). So far, most studies have been performed on serum samples 
derived from adults with different clinical conditions. 
The gold standard for the assessment of iron stores is the amount of stainable iron in a 
bone man-ow aspiration. However, in infants bone aspirations are not easy to obtain. 
The concentration of soluble transferrin receptors could be a promising parameter to 
evaluate the iron status in infants because of its high sensitivity while only a small 
sample volume is required. In the present study the concentration of soluble transferrin 
receptors was studied in the newborn infant in relation to different serum parameters 
of iron metabolism. Bone marrow aspirations could not be studied for ethical reasons_ 
Because the gold standard was lacking, no firm conclusions could be made. The 
concentration of soluble transferrin receptors in Senll11 did not show any correlation 
with either the ferritin or the serum iron concentration. This finding confirms the data 
from earlier studies (23,25). Shortly after birth the concentration of soluble transferrin 
receptors seems to be a parameter which is independent of iron metabolism and can 
not be used for the assessment of iron status. This is confirmed by the observed day to 
day variation during the first days of life. However, additional studies are required to 
select the age ti'om which the soluble transferrin receptor concentration in serum 
correlates with the iron status. 
Both transferrin and its rcceptor carry carbohydrate chains. The role of these 
carbohydrate chains has not been clarilled yet. The microheterogeneity pattern of 
transferrin is modified during certain conditions, probably influencing the interaction 
of transferrin and the receptor (26,27). In this study the microheterogencity of 
transferrin in newborn infants was studied. A shift towards the less sialylated fractions 
could be observed. Especially the 5- and 6- sialo transferrins were decreased. In the 
technique of isoelcctric focllsing the different iso-transferrins are separated depending 
on their isoelectric point. The isoelectric point is mainly defined by the number of 
sialic acid residucs attached to the terminal carbohydrate residue. 
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The shift towards the less sialylated transfetTins that was observed in infants might 
reflect a lower degree of branching of the oligosaccharide chains in the N-terminal 
domain. However, this can also be causcd by a desialylation of the glycans. More 
research is needed on the structure of these glycans but is limited by the volume of the 
sample that can be obtained. 
In adults it has been shown that different isofonns of transferrin have a different 
affinity for the transferrin receptor. In adults it was shown that the affinity of 
transferrin for its receptor is not influenced by the degree of glycosylation. However, 
the iron donation from completely deglycosylated transferrin is decreased compared to 
fully glycosylated transfenin (27). In a hypothetical model one could presume that in 
newborns this deglycosylated transferrin might act as an iron scavenger by binding 
excess of iron without accumulation in the cell. 
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7.1 General discussion 
Iron is onc of the most interesting elements in the human body. It plays a key role in 
many biochemical processes simply because of its property that in an aqueous 
environment it rapidly changes between its two common oxidation states by the uptake 
of release of an electron. Iron is also an essential element so its availability depends on 
the balance between the daily intake and output. 
In man, depletion of iron stores can lead to several systemic abnormalities, anaemia 
often being the first. On the other hand, iron overload is just as harmful since iron acts 
in its unbound state as a transition metal in the production of highly reactive oxygen 
and hydrogen radicals (1). 
The ambiguous re1ationship of man with iron is strained to an even more critical 
balance in infants. Iron deficiency during infancy or childhood may lead to ineversible 
damage affecting long term developmental outcome (2). Newborn infants are highly 
susceptible to the adverse effects of iron. In the brain tissue of these patients high 
levels of SllpCl'oxide and hydrogen peroxide can be found. These oxygen species are 
produced during the process of reperfusion and reoxygenation in perinatal asphyxia. In 
newborn infants detectable levels of unbound iron have been found (3,4), catalysing 
the conversion of these molecules to the highly reactive hydroxyl radical. It is clear 
that the deve10ping brain of the newborn may be damaged by the adverse effects of 
these hydroxyl radicals (5). 
7.1.1 Transferrin receptors on erythroblasts 
Patients presenting with anaemia are often treated with iron for a couple of weeks 
before the final diagnosis is established. Those patients in whom the anaemia is not 
caused by iron deficiency will fail to respond to iron therapy. Iron will accumulate and 
eventually the adverse clinical effects of iron overload will develop without correcting 
the anaemia. 
The cellular uptake of iron is mediated by the transferrin receptor (5). An optimal iron 
uptake by the cell requires an undisturbed binding of transferrin and its receptor. 
During the last decade, there has been increasing interest in the interaction of 
transferrin and its receptor. Under normal circumstances, the expression of cellular 
transferrin receptors is inversely related to the intracellular iron content (6). The 
molecular structure of the transferrin itself, especially the function of the glycans has 
been the target of research as well (7). 
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Using now cytometry the expression of transfelTin receptors can be quantified on 
different cell types. Studying this expression on erythroblasts in patients with different 
types of anaemia may select a subpopulation of patients who are unresponsive to iron 
therapy. The assessment of the expression of membrane-bound transfelTin receptors on 
erythroblasts by flow cytometl)' is a sensitive method and gives direct information on 
the ability of iron uptake by the cell of interest. However, this technique is labour 
intensive and expensive. More important, this technique can only be used on freshly 
drawn bone marrow cells, since the membrane bound transferrin receptor has been 
shown to be destroyed in the process of freezing and thawing. 
As shown in chapter 3, a decline in transferrin receptors on the cell membrane can be 
found in some clinical conditions. This will result in a diminished uptake of iron even 
though the intracellular iron content is decreased. Treatment of these patients with iron 
supplements will not correct the low haemoglobin concentration but will lead to 
accumulation of iron in several organs. This can be easily seen in Prussian Blue 
stained bone marrow aspirations. The diminished expression of membrane bound 
transferrin receptors in anaemia of chronic disease confirms the classical finding of 
abundant iron in the MPS of bone marrow in combination with an (almost) complete 
absence of sideroblasts. 
7.1.2 Soluble transferrin receptors in serum 
The soluble transferrin receptor in serum is considered to be a tnlllcated fragment of 
the membrane bound receptor reflecting the total amount of transferrin receptors on 
different cells, especially erythropoietic cells (8). During the last decade many studies 
have been published describing the clinical significance of the concentration of 
soluble transferrin receptors in serum. However, all studies were performed in a 
research setting, since no commercial assays were available until recently. In the last 
two years different commercial tests have been released on the market for the 
detection of soluble transferrin receptors in serum. The analytical performance of the 
various test kits was in general acceptable for use in daily practice. However, one 
assay could not be introduced into a clinical laboratory without major adjustments to 
the test procedure. 
Care has to be taken in the interpretation of the resuits obtained from the different 
assays. As has been described in chapter 4, the lack of international standardisation of 
these assays makes comparison of the results obtained from different assays 
impossible. The expression of the concentration of soluble tansferrin receptors in mg/l 
by various test kits suggests some standardisation. However, the origin of the purified 
transferrin receptor used as a standard differs not only between different test kits but 
may even vary within the same assay. This may cause problems in the clinical follow 
up of patients attending different laboratories. 
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All tests introduced so far arc enzyme linked immune assays (Elisa's). Apart from 
being a labour-intensive and expensive method this implies that the assay will only be 
done when sufficient samples have been collected which will result in delayed 
reporting of the results to the clinician. This limits the value of this test in a diagnostic 
setting. 
7.1.3 Clinical significance of sTfR in serum 
The two groups of patients who will benefit most from a new and simple test for the 
assessment of iron metabolism are (newborn) infants and patients of all ages 
presenting with anaemia of unidentified origin. It is for this reason that much research 
has been done on the clinical significance of the assay of sTfR in serum. In several 
studies it has been proven that the concentration of sTfR in serum has a high 
sensitivity in the diagnosis of iron deficiency (9). Support for this hypothesis was 
found in chapter 5 of this thesis in which a direct relationship was described between 
an elevated expression of transfenin receptors on the erythroblastic membrane and an 
increased sentm concentration of soluble receptors in iron deficiency. However, the 
diagnosis of uncomplicated iron deficiency is usually straightforward and can be 
established by the combination of a low haemoglobin concentration, rl/ICV, total 
serum iron concentration and low ferritin concentration in serum (l0). 
The diagnosis of anaemia of chronic disease (ACD) is more complex. In clinical 
practice it is often difficult to differentiate this from anaemia caused by other factors 
(11). Those cases in which the anaemia of chronic disease is complicated by iron 
deficiency are especially difficult to diagnose. In chapter 3 it was found that the 
expression of transfenin receptors on erythroblasts in these patients was reduced 
compared to the healthy state. As has been described in chapter 5, no direct 
relationship can be found between the erythroblastic expression of transferrin 
receptors and the concentration of sTIR in serum. The discrepancy between a low 
expression of transferrin receptors on the erythroblastic membrane despite a normal or 
elevated serum concentration of the soluble form in some patients with ACD can be 
explained by shedding of the membrane receptor into the circulation. This limits the 
diagnostic value of the concentration of sTfR in ACD. In those patients in whom iron 
stores are sufficient this concentration can give valuable additional information. 
However, if iron stores are depleted the concentration of sTIR in serum will be the 
result of the combination of an increased concentration as a result of the iron 
deficiency and a normal or increased concentration as a result of chronic disease. The 
resultant concentration will depend upon the severity of each condition. 
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In patients who are suspected of having myelodysplasia the concentration of sTfR 
does not contribute to an em·tier diagnosis. A bone marrow aspiration is still required 
to make the diagnosis. The diagnosis of myelodysplasia always has to be considered in 
every patient who does not respond to iron therapy after three months. The diagnosis 
requires the assistance of an experienced morphologist. 
Since both iron deficiency as well as iron overload may lead to permanent damage to 
cellular proteins and DNA, iron stores in infants have to be kept within narrow limits. 
Iron stores at birth have been shown to cOl1'eiate with iron stores later in childhood 
(12,13). In small children the concentration of sTIR could be an interesting parameter 
for the diagnosis of iron deficiency, especially in those cases where only a limited 
sample volume is available. If in these patients the diagnosis of iron deficiency is 
suspected on the basis of a low haemoglobin concentration, the suspected diagnosis 
can be confirmed by assaying the sTIR concentration in the EDTA-plasma sample. 
This way a second venous blood sampling to obtain a serurn sample for assessment of 
the ferritin concentration is prevented. However, the concentration of sTIR was found 
to be independent of iron metabolism in newborns (chapter 6). The relationship 
between the sTIR concentration in the newborn and gestational age or birth weight 
which was earlier described by Carpani (14) could not be confirmed. Apart from that, 
no extensive studies have been pelformcd to establish age related reference values. 
7.1.4 Transferrin and its reccptor in newborns 
The key process in the cellular iron uptake is the interaction of transferrin, the iron 
transporting protein, with its receptor. 
During the last decade extensive studies have been performed on the glycan 
composition of transferrin. The importance of the glycans for the function of the 
proteins has not been clarified yet (15). However, some clinical conditions have been 
shown to correlate with a different glycosylation pattern of the glycoproteins. For 
example, in the carbohydrate-deficient glycoprotein syndrome a highly aberrant 
glycosylation pattern has been shown to correlate with serious neurological 
abnormalities. In other clinical conditions, like pregnancy, a more physiological shift 
towards higher or less glycosylated proteins can be found (16). This might be an 
adaptation to an altered physiological state. Previous studies have shown that even 
though the affinity of transferrin for its receptor is not influenced by the degree of 
glycosylation of the protein, the iron uptake from aglyco-transferrin is decreased. In 
chapter 6 we describe a shift towards less sialylated transferrin in the newborn. Since 
studies in newborns are always limited by the available sample volume we were not 
able to identify the structure of the glycans in relation to gestational age. If we assume 
that the elevated asialo-transferrin concentration in newborns is representing an actual 
elevation of the aglyco-transferrin concentration this might act as a protection 
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mechanism for adverse effects of the non-proteinbound iron which can be found in 
newborns. In this hypothetical model deglycosylatcd transfclTin serves as an iron 
scavenger clearing the circulation from the non-proteinbound iron from the 
circulation. This iron is then sequestered without taking too much iron to the cell. 
The transferrin receptor is also a glycoprotein. This raises the question whether the 
transferrin reccptor shows the same pattern of glycosylation as transferrin, and if so 
whether the affinity of the transferrin reeeptor for transferrin is influenced by this 
glyeosylation pattern. 
7.2 Conclusions 
From this study it can be concluded that:-
(a) the ineffective response to iron therapy in cases of ACD and MDS can be 
explained by a reduction of transferrin receptors on the erythroblastic 
membrane; 
(b) the concentration of soluble transferrin receptors in serum is directly related to 
the erythroblastic membrane expression only in iron deficiency; 
(c) the discrcpancy between a low expression of transferrin receptors on the 
erythroblastic membrane despite a normal serum concentration of the soluble 
form in some patients with ACD can be explained by shedding of the 
membrane rcceptor into the circulation; 
(d) the concentration of sTIR in a diagnostic setting is of limited use; 
(e) the concentration of soluble transferrin receptors in serum in the newborn is a 
parameter independent of iron metabolism, birth weight and gestational age; 
(f) the shift towards the less sialylated iso-transferrins in the newborn may be part 
of an adaptation process by which unbound iron in the newborn is sequestered. 
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7.3 Future research 
As this study proceeded, more questions have appeared which can only be answercd 
by future research. Over the years, the laboratory techniques will evolve making it 
possible to further explorc the field. 
Thc recent de~elopments in flow cytometry havc made it possible to use three colour 
or even four colour fluorescence techniques in a routine setting. This increases the 
possibilities. In the last few years apoptosis has been an interesting new topic in many 
flow cytometric studies. This raises the possibility of studying apoptosis of the 
erythroblasts in MDS in relation to the transferrin receptor expression on its 
membrane. It would be interesting to pcitorm this study to follow the response of 
individual patients who are treated with iron chelation therapy. Combining the results 
with the serum levels of IL 6 and EPO givcs additional information. This might lead to 
some understanding of why some patients can be treated with erythropoietin to correct 
anaemia, while others become less dependent on red cell transfusions as a result of 
iron chelation. 
In newborns more research is required on different aspects of iron metabolism. It 
would be interesting to identify the agc-related glycan structure on transferrin. Apart 
from these issues it will be necessary to assess age-related reference values of soluble 
transferrin receptors for new barns and children of any age. 
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8.1 Summary 
Iron is essential for life. It has its main function in the transport of oxygen through the 
body. Apart from that, iron is a key element in many biochemical processes in cell 
metabolism. 
The iron balance in the human body almost completely depends on the dietary intake. 
The iron status is regulated at the level of iron uptake instead of at the level of iron 
excretion. Under normal circumstances the iron intake matches the daily losses but in 
some conditions this balance is disturbed due to an increased loss. In certain age 
groups in which rapid growth and development put an extra demand on iron stores 
iron deficiency easily develops. Other groups of patients at risk of developing iron 
deficiency are females in the fertile period and during pregnancy. Iron deficiency can 
lead to several systemic abnormalities, anaemia often being the first. The most serious 
results of iron deficiency at an early age are impairment of cognitive performance and 
motor development. Some studies have shown that these abnormalities persist despite 
extended oral iron therapy with adequate haematological response. 
Should the state of iron deficiency be cured as soon as the diagnosis has been made to 
prevent long term consequences, iron overload should be prevented as well. 
Non-proteinbound iron acts as a transition metal catalysing the formation of highly 
reactive free radicals which can lead to permanent damage to intracellular protcins and 
DNA. 
In the daily clinical practice of the general practitioner anaemia is one of the most 
frequent diagnoses. In many cases the anaemia is caused by iron deficiency. The 
diagnosis of iron deficiency is usually straightforward, requiring minimal diagnostic 
skills can be proven if a short period of iron suppletion leads to an increased 
haemoglobin concentration. Sometimes, however, the symptoms are masked by other 
diseases or the laboratory tests are disturbed as a result of other deficiencies or 
superimposed infections. In these patients it may be difficult to differentiate iron 
deficiency from other causes of anaemia in which the administration of iron may cause 
adverse effects. 
The cellular uptake of iron is mediated by the transferrin receptor. The transferrin 
receptor is a transmembrane glycoprotein present on most cells. After the binding of 
transferrin to the receptor, the transferrin-iron complex is taken up by the cell and iron 
release takes place. The number of transferrin receptors on the cell membrane depends 
on the intracellular iron concentration. Soluble transferrin receptors can be found in 
serum. The concentration of these soluble transferrin receptors is related to the number 
of membrane-bound receptors and has been described as being a sensitive parameter 
of iron status. 
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This thesis describes a study of transfcrrin receptor expression on the etythroblastic 
cell membrane in relation to soluble transferrin receptors in serum. Different groups of 
patients were studied. 
Chapter 1: 
This chapter describes a summary of the latest views on iron metabolism. The 
different processes in iron uptake, iron transport and iron storage are described. An 
overview is given of the main causes of anaemia. Special attention is paid to iron 
metabolism during pregnancy and foetal development. 
Chapter 2: 
The techniques used in the experiments in this thesis me described in this chapter. 
Chapter 3: 
The presence of transferrin receptors on erythroblasts in patients with iron deficiency, 
anaemia of chronic disease and myelodysplastic syndrome is studied by two colour 
analysis on a flow cytometer. CD 71 is used to quantify the number of transferrin 
receptors and GL Y -A to identify erythroblasts. In this study an cxplanation is found 
for the decreased iron uptake in erythroblasts despite sufficient storage pool iron. 
Chapter 4: 
In this chapter the analytic pelfonnances of recently introduced assays for soluble 
transferrin receptors in serum are described. In a small clinical study serum samples of 
patients \vith anaemia of chronic disease, iron deficiency and myelodysplastic 
syndrome are analysed as well as sera obtained from healthy volunteers. The problems 
in international standardisation are discussed. 
Chapter 5: 
It has been described in the literature that the concentration of soluble transferrin 
receptors in serum is directly related to the total amount of tissue receptors. In this 
chapter this relationship is studied. The expression of transfcrrin receptors on the cell 
membrane of erythroblasts in patients with different forms of anaemia is analysed with 
tlow cytometry. At the same time the concentration of soluhle transferrin receptors 
(sTtRs) is analysed in serum. The relationship described in the literature between the 
concentration of soluble transferrin receptors in serum and the number tissue receptors 
can not be confirmed for all diagnoses. 
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Chapter 6: 
II has been known for a long time that iron deficiency in children may effect physical 
and cognitive development irreversibly. On the other hand, iron overload is just as 
harmful. In adults the concentration of soluble transferrin receptors in serum has 
proven to be a reliable predictor of iron statllS. 
In the present study we investigate the usefulness of the concentration of sTIR in 
serum in the assessment of iron metabolism in the newborn. Infants born after an 
uncomplicated labour are compared to infants in the intensive care unit. 
The interaction of transferrin and its receptor requires a structurally normal protein. In 
this chapter we also describe a study concerning the glycan structure of the transferrin 
molecule. 
Chapter 7: 
This chapter contains the general discussion and conclusions that can be drawn from 
the studies presented in the previous chapters. 
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8.2 Samenvatting 
IJzcr is van levensbelang, niet alleen omdat het onmisbaar is voor het transport van 
zlIurstof door het lichaam, maar ook door de slelltelrol die het bekleedt in de 
stofwisscling van de eel. IJ zer is een essentieel element, wat betekent dat de mens 
voor de toevoer volledig atllanke1ijk is van de voeding. De opname en uitscheiding 
van ijzer is in het idea le geval vrijwel in evenwicht en beweegt zich binnen nauwe 
grcnzen. Door de toegenomen behoefte aan of het verhoogde verlies van ijzer tijdens 
onder meer groei, zwangerschap, borstvoeding en menstl11atie kan gemakkelijk een 
tekort ontstaan. Dit kan aanleiding geven tot blijvende schade, zich uitend in 
bijvoorbeeld eonccntratiestoornissen en lccrproblemen bij kindcren. 
Even schadelijk als een ijzertekort is cen teveel aanlichaamsijzer. Het ijzer is in staat 
om de vorming van zeer reactieve elementen te bevorderen, welke de cellulaire 
eiwitten en het DNA kunnen beschadigen. 
Bloedarmoede komt in de dagelijkse praktijk van de hllisarts veelvnldig voor. In veel 
gevallen is de oorzaak een gebrek aan ijzer en is dit gemakkelijk vast te stellen met 
minimale diagnostiek en omdat de klaehten van de patient al in die richting wijzen. 
Een proefbehandeling met ijzer leidt dan al tot het gewenste resultaat, namelijk een 
correetie van de bloedarmoede. Soms eehter, wordt het ijzergebrek gemaskeerd omdat 
bijkomende ziekte de diagnostiek vertroebelt of is hettekort aan ijzer niet de enige 
oorzaak van de bloedarmoede. Daarnaast kan blocdarmoede ook een heel andere 
oorzaak hebben, waarbij behandeling met ijzer jllist schadelijk kan zijn. In deze 
gevallen is vaststellen van de oorzaak van de bloedannoede geeompliceerd. Het is dan 
oak van bclang om in een vrocg stadium de juiste oorzaak van de bloedannoede 
adequaat vastte stellen. Het zal dllidelijk zijn dat dit eens te meer geldt voor jonge 
kinderen. 
Voor de opname van ijzcr in de eel is de "transferrinereeeptor" essentieel. Dit eiwit 
bevindt zich aan het oppcrvlak van de eellen fungeert als "hcrkennerH van het 
transferrine, het ijzertransporterend eiwit in de bloedbaan. Door koppeling van het 
transferrine aan de transferrinereceptor kan het ijzer worden opgenomen in de eel. Het 
aantal transferrinereeeptoren op het celoppervlak zot! cen maat zijn voor de behoefte 
aan ijzer. 
Het onderzoek dat beschreven wordt in dit proefsehrift heeft de transferrinereceptor 
aIs eenlraal thema. Er is zowel gckeken naar transferrinercccptoren op de 
eelmembraan van de jonge voorlopcreellen in het beenmcrg als naar de eoneentratie 
van oplosbare transferrinereeeptoren in de bloedbaan. Deze oplosbare reeeptoren zijn 
fragmenten van de reeeptoren op de celmembraan en komen in de bloedbaan door 
afsplitsing van de eel. Verschillende patientengroepen werden bestudeerd. 
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HoofdsllIk J: 
In dit hoofdstuk wordt cen samenvatting gegevcn van de meest reecntc inzichtcn op 
het gebied van de ijzerstofwisseling. Hierbij komen de verschillende stappen in het 
proees van ijzeropname in hct lichaam, ijzertransport door het liehaam en de opname 
van ijzer door de eel en dc opslag in de eel aan de orde. Speciale aandacht wordt 
gegeven aan de ijzerstol\visseling tijdens de zwangerschap en bij de pasgeborene. 
Tevens wordt een besehrijving gegeven van de Illcest voorkomende oorzaken van 
blocdarmoede. 
HoofdsllIk 2: 
In dit hoofdstuk wordt een beschrijving gegeven van de methoden en de technieken 
die gebntikt zijn in dit onderzoek. 
H()(!fdsllIk 3: 
De transferrinereeeptoren op het oppervlak van de jonge rode voorlopercellen in het 
beenmerg wcrdcn in kaart gebraeht bij patienten met versehillende vormen van 
blocdannoede. De transfelTincreceptoren op het ecloppervlak werdcn gemctcn mct 
behulp van tloweytometrie, een tcchnick waarmee bepaaldc eclkenmerken kunnen 
worden zichtbaar gemaakt. Er wordt gebruik gemaakt van een tluorcsecrcndc stof die 
gebonden is aan een antistof welke specifick rcageert met een mcmbraaneiwit. 
In deze studie, die cen beperkt aantal patienten omvatte wcrd een verklaring gevonden 
voor de bcvinding dat patienten met bloedarmoedc als gevolg van ecn chronisehc 
ziekte geen ijzer in kunnen botlwen, ondanks dat er cen voldoende voorraad ijzer 
aanwezig is. Bij patienten met myelodysplasie kon de ineffeetieve groei van de jongc 
rode cellen zichtbaar gcmaakt worden. 
Hoo/dslllk 4: 
In dit hoofdstuk worden de analytisehe prcstaties beschreven van de cOllunerciele 
testkits dic momenteel verkrijgbaar zijn en waarmcc de coneentratic van de oplosbarc 
transferrinercccptaren gemeten kan warden. De verschillende kits bleken nogal 
verschillend te presteren. In een geval bleek dat de bepaling nog niet geschikt was 
voor gebruik in de routine. Er werd uitgebreid aandacht besteed uun de noodzakelijke 
internationale standaardisering van de bepalingen. Nlet de vcrkrijgbare testen werd 
ook cen korte klinisehe studie verricht, waarbij nagegaan werd of de bepaling van de 
oplosbare transferrinereceptoren in het bloed kon bijdragen in het onderscheiden van 
de vcrschillende vormen van bloedarmoede. 
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HoofdsllIk 5: 
Volgens de internationale literatuur zou de concentratie van oplosbare 
transferrinereceptoren in de bloedbaan direct afhangen van de hoeveelheid van deze 
receptoren op het celoppervlak. In dit hoofdstuk werd beschreven hoe bij de 
verschillende patiCntengroepen de concentratie van transferrinereceptoren in de 
bloedbaan zich vcrhoudt tot het aantal transferrinereceptoren op het celoppervlak. De 
veronderstelde dirccte reIatie was niet bij aUe diagnosegroepen even duidelijk 
aanwezig. 
Hoofd.l'llIk 6: 
Bij pasgeborenen en bij le vroeg geborenen is nagegaan of de bepating van oplosbare 
transfcrrinereceptoren een plaats verdient in de cvaluatie van de ijzerstatus van het 
kind. Daar er slcchts cen zeer klein monstervolume nodig is voor de bepaling is deze 
1110gelijk interessant. Voor de binding van transferrine aan de transfcrrinereceptor is de 
moleculairc structuur van het transferrine zelf ook van belang is. Omdat hierover bij 
gezonde kinderen niets bekend was is deze structuur ook bestudcerd. 
Hoo./dsllIk 7: 
In dit hoofdstuk worden de conclusies uit de overige hoofdstukken samengevat en 
worden aanbevelingen gegeven voor verdel' onderzock. 
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List of abbreviations 
ACD : anaemia of chronic disease 
CD : cluster of differentiation/cluster of designation 
CFU-GEM : colony forming unit: granulocyte-erythroblast-megakaryocyte 
CFU-GM : colony forming unit: granulocyte-macrophage 
CMML : chronic myelo-illonocytic leukernia 
DNA : dcsoxyribo nucleic acid 
EIA : enzyme immuno assay 
ELISA : enzyme linked immuno sorbent assay 
EPO : erythropoietin 
ESR : erythrocyte sedimentation rate 
FAB : French American Britisch cytomorphological classification of acute 
leukemias 
Fe : iron 
FITe : fluorescein isothiocyanate 
FSC : forward scatter signal 
GL Y-A : glycophorin A 
HRP : horse radish peroxidase 
Ig : immunoglobulin 
IRE : iron responsive element 
IRE-BP : iron responsive element binding protein 
LDH : lactate dehydrogenase 
MCV : mean corpuscular volume 
MCH : mean corpuscular haemoglobin 
MDS : myelodysplastic syndrome 
MEIA : microparticlc enzyme immunoassay 
MESF : molecules of equivalent soluble fluorochrome 
:NIPS : mononuclear phagocytic system 
mRNA : messenger R1'l"A 
Mw : ~IIolccular weight 
IQ : intelligence quotient 
kDa : kiloDalton 
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PE 
PM 
RA 
RAEB 
RAEB-t 
RARS 
RNA 
RPM! 
sd 
SSC 
sTIR 
TBARS 
TCA 
Tf 
TtR 
v/v 
w/v 
: phycoerythrin 
: photomultiplier 
: refractory anaemia 
: refractory anaemia with excess of blasts 
: refractory anaemia with excess of blasts in transformation 
: refractory anaemia with ring sideroblasts 
: ribo nucleic acid 
: Roswell Park Memorial Institute 
: standard deviation 
: sideward scatter signal 
: soluble transferrin reccptor 
: thiobarbituric acid reactive species 
: trichloric acetic acid 
: transferrin 
: transferrin receptor 
: volume per volume 
: weight per volume 
Abbrevatiolls 
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gewees!. Als ik er eeht niet meer in geloofde zette jij door. Het proefsehrift is dan oak 
een beetje van jou. Jouw hulp bij statistiek, het tekenen van figuren en de uiteindelijke 
layout is heel waardcvol gewecst. Wc hocvcn nu de "lap top" niet mcer mee te ncmcl1 
op vakantie en de zondagen achter de computer behorcn oak tot het vcrlcden. 
Misschien kan ik je nu cens komcn amul10edigen op het hockey veld. 
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Curriculum Vitae 
De schrijfster van dit proefsehrift werd geboren op 9 juli 1961 te Kapelle-Biezelinge. 
In 1979 haalde zij het gymnasium B diploma. In 1980 begon zij aan de studie 
geneeskundc aan de Erasmus Univcrsiteit Rotterdam. Het kcuze-onderzoek werd 
uitgevoerd bij de afdeling Chemische Pathologie van deze universiteit en had als 
ondenverp "microheterogeniteit van transferrine bij alcoholisten". In het kader van dit 
onderzoek wcrkte zij in de zomcrs van 1984 en 1985 bij Phannacia in Uppsala, 
Zweden. 
In 1987 begon zij aan de opleiding tot arts klinische chemie (Iaboratoriumarts) in het 
Drechtsteden Ziekenhuis in Dordrecht (opleiders: eerst dl'. He Lequin, later dl'. RB 
Dinkelaar). In het kader van haar opleiding haalde zij het diploma 
stralingsbeschenning niveau 3. In 1991 werd zij ingcschreven in het specialistcn 
register van de SRC. 
Op I april 1991 trad zij toe tot de Maatschap vaor Klinische Laboratoriumdiagnostiek 
in het Sophia Ziekenhuis in Zwolle, met als aandachtsgebied de hemato-oncologie. 
Hier wcrd op 1 januari 1994 cen begin gemaakt met het hier beschrevcn onderzoek. 
Eind novembcr 1996 verwierf zij de SRC erkenning als oplcidcr voor haar 
specialismc. 
Nu ccrst enkele jarcn actief geweest te zijn in de beroepsbelangen commissie van de 
Vereniging Artsen Laboratoriumdiagnostiek, de \Vetenschappelijke Vereniging van de 
laboratoriumartsen, is zij sinds augustus 1994 sccrctaris van deze vercniging. AIs lid 
van de wetenschapscommissie is zij mcde-verantwoordelijk voor de organisatie van de 
jaarlijkse wetenschapsdag. Sinds 1 januari 1997 heeft zij zitting in de plenaire visitatie 
commissie van de V AL en is zij plaatsvcrvangend SRC lid. 
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8 
De noodzaak tot meer inbrcng van de inboratoriuIllspecialist in het klinische proces 
rcchtvaardigt het bestaan van een eigen register \'oor de arts klinische chemic. 
9 
De titel "arts klinische chemie ll dient vcrvangcll te warden door Hlaboratoriumarts". 
10 
De plaats van cen laboratoriulllspecialist is in het eigcn ziekcnhuis. 
11 
Het bewerken vall een proefschrift naast een volledigc baall voorkomt fixatie en leidt 
daardoor tot een bredcre vorming. 
12 
Bij aardappelmoeheid is Seresta de eerste kens. 
13 
In tegcnstelling tot wat Leonardo da Vinci beweert is niet de heeldende kunst maar de 
ll111ziek de hoogste aller hUlstell. 
14 
Het beperkcn van de Nocturncn van Chopin tot nachtmuzick doet onvoldoendc rcehL 
nan de schoonheid van deze ll1uziek. 
15 
Dicet is meestal die eet niet. 

